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Abstract 
Bacterial infections are considered the second main cause of death worldwide and the third 
main cause of death in the developed countries and as a result, many antibacterial coatings 
have been prepared in order to fight the different strains of bacteria and decrease the 
mortality rates. Natural antibacterial products become of great interest nowadays and their 
use is preferred over the synthetic products in order to overcome the resistance to the 
synthetic antibiotics. A wide variety of antibacterial coatings have been developed ranging 
from polymeric to polymer Nano-composites (PNCs) materials. Using nanomaterials as 
fillers within polymer matrices have been reported to enhance the antibacterial properties 
significantly. The polymeric nanoparticles (NPs) are promising for natural antibacterial drug 
delivery.  
 In this study, two types of Garlic oil nano-composites (GO-NCs) have been developed by 
using two polymers which are poly lactic-co-glycolic (PLGA) and poly lactic-co-
glycolic/poly ethylene glycol (PLGA/PEG) mixed with garlic oil (GO). The two polymer 
Nano-composites were named PLGA-GO-NCs and PLGA-PEG-GO-NCs respectively. 
Single emulsion/solvent evaporation (SE/SE) technique was involved in the preparation of 
the different nanocomposite formulations. The polymers conjugated with GO were prepared 
at three different homogenization time intervals (5, 10 and 15 min.) at the same 
homogenization speed of 11,000 rpm. All the preparation parameters, such as the 
concentration of polymers, concentration of GO, amounts of surfactant used (polaxmer 407) 
and the homogenization speed, were kept constant to identify the effect of the 
homogenization time on the physicochemical properties and the antibacterial activities of the 
PNCs.  In addition, the effect of other factors such as the effect of solution settling, the use of 
Buchner funnel in solution filtration, the use of biological filters in solution filtration and the 
effect of mechanical shaking the solutions by using vortex stirring on the different 
formulations were carefully examined. The particle sizes, zeta potential and poly dipsersity 
index (PDI) and GO% in each formulation have been measured. The morphological 
examination of the prepared nanocomposite formulations was carried out by using Scanning 
Electron Microscope (SEM), and the chemical structural characteristics were examined by 
using Fourier Transform-Infra-red spectroscopy (FT-IR) and Ultraviolet-Visible 
iv 
 
spectrophotometry (UV-vis). In addition, antibacterial assessment has been carried out 
against Eichercia Coli (E. coli) (ATCC 8739) as a Gram-negative bacterium, and 
Staphylococcus aureus (S. aureus) (ATCC 6538) as a Gram-positive bacterium using Colony 
Counting Method (CCM).  
The results revealed four important factors that need to be considered during the preparation 
of GO NPs which are (i) settling of the solutions, (ii) filtration through biological filters, (iii) 
Buchner filtration and (iv) vortex stirring of solutions. These factors play a crucial role in 
controlling the size and stability of PNCs. Furthermore, we have observed that the addition of 
PEG to the PLGA-GO formulations has a significant effect on decreasing the particle sizes 
and increasing the GO% in the formulations. These results could be promising in producing 
polymeric drug/extract NPs of small particle sizes, high stability and of pronounced 
antibacterial activity which is stronger than the original dtug/extract. 
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Thesis Scope and Objectives  
In this study, the main objectives are divided into the following activities: (i) preparation of 
PLGA-GO-NPs and (ii) PLGA-PEG-GO-NPs by the (SE/SE) technique using 
homogenization with three different homogenization time intervals (5, 10 and 15 min.) at the 
same homogenization speed of 11,000 rpm. In addition, the effects of solution settling, 
filtration by using biological filters and Buchner funnel were carefully examined as 
illustrated in (Figure I).  
 
Figure I. A summary for the steps that were followed for the preparation and the 
characterization of different polymeric NPs conjugated with GO. 
 
The preparation steps were accompanied by a complete morphological examination (by 
SEM) and chemical structural characteristics (by FT-IR and UV-Visible spectrophotometry) 
as well as particle size, PDI and zeta potential determination. Moreover, the antibacterial 
activities for each formulation were investigated and compared to that of the original GO. 
The objective of this study is to prepare a polymeric NPs conjugated with GO that have the 
smallest, most stable and uniform sizes with enhanced antibacterial activities in comparison 
to the original GO. The GO NPs were prepared in order to enhance the antibacterial activities 
of GO against different types of food borne pathogens and to enhance the different 
pharmacological activities of GO in general such as anticancer, antioxidant, etc. 
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Chapter 1: General Introduction & Literature review 
1.1 Introduction 
1.1.1 Natural Products 
Natural products such as herbs, plant extracts and oils were widely used in the folk medicine to 
treat and prevent a wide variety of diseases such as microbial infections and cardio-vascular 
diseases. In addition, natural products have also been used as dietary supplements and have 
become one of the basis foundations behind the discovery and the design of synthetic 
pharmaceutical drugs that are used nowadays. This is mainly because their natural active 
constituents possess many pharmacological activities.
1
 In this regard, there is a great tendency 
nowadays to replace synthetic drugs with natural components due to the high efficacy of the 
latter ones when applied to the human body and their biosafety, which are less likely to cause 
allergic reactions, and more importantly that they are biocompatible when compared to most of 
the synthetic drugs. There are many serious diseases that increase the mortality rates worldwide 
such as cancer, cardio-vascular diseases and fatal bacterial infections.
1
  Numerous research 
studies and published articles on using natural products to fight some of the most common 
diseases have been reported.  
The use of natural products such as gums, myrrh, pomegranate, grapes and castor oil by ancient 
Egyptians in treatment of different diseases was recorded on the walls of their temples. Egypt has 
a unique climate and geographical conditions that made it the only source for over than 342 
species of medicinal plants such as Black seed, anise, coriander, fennel and Aloe verae. 
2, 3
  
1.1.2 Applications of the natural products 
Natural products are widely involved in many applications and their use is preferred over the 
synthetic products. A few examples are described in this section. 
Gingko biloba contains flavonoids and terpenoids named ginkgolides and bilobalide. It is used 
mainly as a nootropic agent (drug that enhances memory and other cognitive functions)  because 
it increases blood flow to the brain with the main function of improving memory and might have 
a brain supporting effect in Alzeimer's disease.
4
 Also, it can be used in treatment of hypertension, 
sexual dysfunction and in treatment of multiple scelerosis.
4
  
5 
 
Curcumin (Figure 1.1) is a natural chemical ingredient that is extracted from Curcuma longa 
rhizome. Its o-methoxy phenol derivative was found to have potential anti-cancer activities. 
These activities were attributed to its ability to prevent proliferation and invasion of cancer cells 
by decreasing nuclear factor NF-αB and β-catenin transcription factors inside the cell. In 
addition, curcumin is able to prevent metastasis and it acts as an antioxidant by scavenging free 
radicals. 
5
  
 
Figure 1.1. The chemical structure of curcumin.
6
  
Panax ginseng roots (Korean or Asian Ginseng) contain saponins called ginsenosides, as the 
main active ingredient, which are classified into two main groups: protopanaxadiols and 
protopanaxatriols. Panax ginseng is widely used in treatment of erectile dysfunction and in 
increasing the sexual drive in males.
7
 In addition, ginsenosides present in Panax ginseng can be 
used as a prophylaxis against cancer (especially for smokers) and as an energy booster after 
exhausting exercises. These activities are due to the strong antioxidant activity of ginsenosides 
that enable them to fight and prevent the formation of different free radical hydroxides and 
superoxides that are known as Reactive Oxygen Species (ROS) and as a result, they decrease the 
oxidative stress inside the body and inhibit lipid peroxidation.
8
  
Natural products have many biomedical applications as shown earlier, but the most concerning 
biomedical application for this thesis work is the antibacterial action. 
1.2 Bacterial infections  
1.2.1  Food borne micro-organisms 
Bacterial infections are considered the second main cause of death worldwide and the third main 
cause of death in the developed countries where food is considered as one of the major causes for 
bacterial infections. Food-borne illness is a concerning problem that is caused by ingesting food 
products and/or beverages that are contaminated by pathogenic micro-organisms. The pathogens 
that cause food-borne illness might be either bacteria such as Listeria monocytogens, 
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Staphylococcus aureus, Salmonella and Escherichia coli 0157:H7, or viruses such as 
Noroviruses and hepatitis A or fungi such as Aspergillus flavus which produces mycotoxins 
(Aflatoxins).
9
 The symptoms of food-borne illness vary, but there are some common symptoms 
such as vomiting, diarrhea, fever, headache and abdominal spasms. Sometimes, a person does 
not develop clear symptoms and as a result, a stool specimen is required. Geriatric patients are 
more susceptible to food-borne illness as they lack adequate acidity in stomach, which allows 
pathogens to pass into the intestinal tract. They have slow digestion resulting in the long stay of 
pathogens in their intestine and they also have weak immunity that decreases their resistance to 
the pathogens.
9
 As a consequence, the Food and Drug Administration (FDA) stated a group of 
food products that should not be consumed by elderly such as raw fish, soft cheese, 
unpasteurized milk and lightly cooked egg. Many attempts are performed in order to reduce or 
prevent food borne diseases are described below: 
i- Pasteurization of milk and dairy products. 
ii- Applying good hygiene practices during canning to prevent Clostridium botulinum. 
iii- Sterilization and purification of drinking water. 
iv- The use of irradiation as a modern technique for preservation and sterilization of food 
products such as gamma irradiation. 
Although the above methods were involved in the prevention of food-borne diseases, many 
outbreaks of food-borne illness are recorded. Food-borne outbreaks are defined, according to the 
Center of Disease Control and Prevention, as the presence of two or more similar cases of illness 
that are resulted from ingestion of common type of food products.
9, 10
  
As a result, according to FDA, many types of food stuffs are not recommended to be consumed 
by humans as they possess high susceptibility to cause food borne illness. Examples for these 
food stuff are raw fish and shellfish, raw unpasteurized milk and milk products, soft cheese such 
as brie, feta and Mexican-style cheese, raw or slightly cooked egg products such as salad 
dressings and raw meat and poultry.
11 
In this context, there is a great need to develop new natural 
anti-bacterial formulations that will be able to prevent and treat different types of food borne 
micro-organisms. 
Food borne illness is caused mainly by food borne bacteria and food borne viruses as mentioned 
earlier, the difference between them is summarized in Table 1.1. 
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 Table 1.1. Summary of the major differences between food borne bacteria and food borne 
viruses.
12, 13
 
 Food-borne bacteria Food-borne Viruses 
1-Cell envelope               (+ve)                 (-ve) 
2-Replication in food 
and water 
They are able to replicate in 
food and water. 
They are not able to replicate in 
food and water as they need 
living cells in order to replicate. 
3-Number of particles 
that can cause illness 
In most cases, many particles 
are needed to produce illness. 
Very few particles are able to 
cause illness. 
4-Stability outside the 
host 
Most of them are affected and 
killed by heat and 
disinfectants. 
They are stable and relatively 
resistant to acid, heat and 
disinfectants. 
5-Effect on food color, 
smell and taste 
Some types can affect food 
color and smell such as 
Pseudomonas. 
They do not affect the smell, taste 
or color of food. 
6-Presence in stool present present 
7-Examples i-Brucella 
ii-Clostridium botulinum 
iiiEnterotoxigenic E. coli 
(ETEC) 
iv-Listeria monocytogenes 
i-Hepatitis A virus 
ii-Noroviruses 
 
1.2.2 Natural antimicrobials 
There is a great tendency nowadays to replace synthetic antimicrobials with natural ones in the 
treatment and the prevention of food borne micro-organisms and relate these natural products to 
the modern drug discovery and modern-targeting systems. The use of natural antimicrobials is 
promising and is preferred over the synthetic ones for the reasons that are summarized in Table 
1.2. 
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Table 1.2. Summary of the main advantages of natural antibiotics over synthetic antibiotics.
14, 15
 
 Natural antimicrobials Synthetic antimicrobials 
1-Resistance No resistance. Suffer resistance from 
different microbial strains. 
2-Effect on normal flora Do not affect the normal 
flora. 
Kill the normal beneficial 
flora inside the intestine. 
3-side effects Possess few side effects and 
show no allergic reaction. 
Most antibiotics have many 
side effects and show fatal 
allergic reactions. 
4-Cost Dependent on the method of 
extraction. 
Expensive 
5- Challenges Sensitivity, selectivity, 
volatility and solubility 
Many side effects that might 
be fatal in some cases. 
 
The different classes and mechanism of action of synthetic antibiotics are summarized in Figure 
1.2. The majority of antibiotics exert their action by inhibiting either the protein synthesis (such 
as aminoglycosides and tetracyclines) or cell wall synthesis (β lactams). Some classes such as 
quinolones exert their antibacterial action through inhibiting DNA synthesis while sulfonamides 
inhibit the synthesis of metabolites that are needed by the bacteria to synthesize nucleic acids. 
15
                  
 
Figure 1.2 A schematic representation of different synthetic antibiotics and their mode of 
actions. 
15 
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The examples and mechanisms of action of natural antibiotics are represented as follows: 
Essential oils (EOs) 
Essential oils are aromatic, natural and volatile liquids that are formed inside different plant parts 
(mainly leaves and flowers) by different metabolic pathways in order to protect the plants from 
insects and micro-organisms. EOs have many industrial applications such as synthesis of 
perfumes and soaps. In addition, they have biomedical applications due to their antimicrobial 
activities. 
16 
 
The structural formulas of different EOs that have been reported to possess antimicrobial actions 
are summarized in Figure 1.3. 
                            
 
 
Figure 1.3 A schematic representation of different structural formulae of some EOs that have 
anti-microbial activities. 
16
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The anti-microbial activity of EOs (Figure 1.4) is attributed to the following reasons:  
They are hydrophobic in nature and this enables them to: 
a- Penetrate and damage the bacterial cell wall and mitochondria. 
b-  Denaturate the membrane proteins by unfolding and/or conformational changes to the 
proteins structure. Protein denaturation is due to an external stress such as PH, organic 
solvents of high concentrations, inorganic salts or temperature. Protein denaturation leads 
to disruption of cell activity. 
c- Increase the bacterial membrane permeability leading to leakage of critical cell contents 
and ions outside the bacteria causing its death. 
d- Cause coagulation of cell contents. 
e- Cause disturbance in the electron flow and active transport. 
In addition, there is a direct relationship between the percentage of phenolic compounds and 
hydroxyl groups in the EOs and the antibacterial activity against food borne pathogens. 
16, 17
 
 
Figure 1.4 A schematic representation showing the different antibacterial mechanisms of 
action of EOs. 
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However, most of EOs have many side effects such as poor solubility, high volatility and 
poor delivery inside the body and as a result, there is a great need to prepare different 
formulations that overcome these side effects as will be discussed later. 
Chitosan 
11 
 
Chitosan is nitrogen containing compound (mucopolysaccharide) that is prepared from 
partial de-acetylation of chitin which is isolated from shellfish sources such as crabs, 
shrimps, locust, etc (Figure 1.5) Chitosan has many biomedical and pharmaceutical 
applications such as synthesis of wound dressings, basic component for tissue engineering 
and as a natural wide spectrum antimicrobial agent. 
18, 19 
 
Figure 1.5 The chemical structures of (a) chitin and (b) chitosan.
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The anti-microbial activity of chitosan is dependent on its molecular weight and it is more 
effective against viruses and fungi than bacteria, and more effective towards Gram (–ve) bacteria 
than Gram (+ve) ones. 
Chitosan anti-microbial activity is attributed to the following reasons: 
a- Being positively charged, chitosan binds to the negative charge on the surface of bacterial 
cell wall causing agglutination of the cell wall resulting in increasing the cell wall 
permeability and leakage of the intracellular components. 
b- Chitosan is a chelating agent that chelates the effective metals needed by the bacteria 
resulting in the inhibition of the enzymatic activity inside the bacteria and inhibiting the 
microbial growth. 
On the other hand, the main disadvantage of chitosan is its limited solubility as it is soluble only 
in acid media and as a result, this can affect negatively its anti-microbial activity and its 
distribution inside different body organs.
20, 21 
 
Garlic 
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Garlic (Allium sativum L.) in addition to its use as a spice in food, was used in the traditional 
Chinese Medicine 3000 years ago in the treatment of headaches, intestinal worms, tumors and as 
an insecticide. Garlic was demonstrated to inhibit the growth of a wide range of bacteria, fungi 
and viruses. In addition, nowadays garlic is used as anti-cholesterol, anti-platelet, anti-
thrombolytic, anti-hypertensive, antioxidant and anti-inflammatory and anticancer natural 
medicine. 
(22-24)
 
Garlic has many forms which are either natural extracts, powder or oil. Garlic contains 
organosulphurous compounds, but the main active ingredient is allicin (Figure 1.6a). Allicin 
represents about 70% of the thiosulfinates present in garlic and it is responsible for garlic aroma 
and major medical activities. Allicin is formed from Alliin by the action of Allinase enzyme 
upon crushing of the garlic cloves as presented in Figure 1.6b. 
 
Figure 1.6 (a) Allicin chemical structure, (b) The formation of allicin from alliin by the action of 
alliinase enzyme) 
25, 26
 
GO is prepared by crushing garlic cloves to release allicin then heating it up to 100 
o
C and 
finally, steam distilling it. GO contains two major thiosulfinates products which are diallyl 
disulfide and diallyl trisulfide (Figure 1.7).
27
 
 
Figure 1.7 The chemical structures of (a) diallyl disulfide and (b) diallyl trisulfide.
25
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The organosulphourous compounds present in garlic are able to interact with the sulfa hydryl 
(SH) groups of bacterial proteins causing their denaturation. Besides, garlic is able to interact, 
through thiol-disulfide exchange, with thiol containing enzymes, needed for bacterial metabolism 
and nutrition, such as alcohol dehydrogenase and cysteine proteases. As a result, garlic was 
reported to be potent antimicrobial against a wide range of bacteria such as Helicobacter pylori, 
Pseudomonas aeruginosa, E.Coli, Salmonella, S. aureus, Clostridium and streptococcus. 
Moreover, garlic was reported to be effective against many types of fungi and parasites such as 
Trichomonas vaginalis, Candida albicans and Cryputococcus neoformans. 
21, 28, 29, 30 
Furthermore, garlic was also reported to have very strong anticancer activities and anti-
proliferative effect on many types of cancers including colon, mammary and endometrial cancer. 
This anticancer activity of allicin is due to its antioxidant activity where it attacks the hydroxyl 
free radicals and prevents the superoxide formation and as a result, it acts as a free radical 
scavenger. Besides, the organosulfur compounds present in garlic such as diallyl sulfide, diallyl 
disulfide and s-allylcysteine are involved in the anti-cancer activity of garlic through inhibiting 
some metabolic and signaling pathways that are responsible for cancer such as mitogenic 
machinery, phosphorylation of proteins, calcium transport and hormonal metabolism.
31
 
On the other hand, garlic and GO suffer from some drawbacks such as strong odor, water 
insolubility and volatility which hinder their use in pharmaceutical formulations. 
In summary, natural products are very promising potential candidates to replace synthetic drugs 
in the treatment and prevention of many diseases and especially bacterial infections while 
suffering from some drawbacks. As a result, there is a great need to prepare modern formulations 
that are able to overcome these drawbacks as will be discussed in the following section. 
22
 
1.3 Nanotechnology and its application in biomedical field 
Nanotechnology has shown a great potential nowadays in the pharmaceutical and biomedical 
fields and is considered to be a revolutionary approach to prevent and treat diseases. 
“Nano” is a Greek word which means “dwarf” or “small” and according to the National 
Nanotechnology Initiative (NNI), Nanotechnology is defined as the science dealing with the 
matter at dimensions of 1-100 nm (where 1nm = 10
-9
 m).
32 
There are many forms of 
14 
 
nanomaterials that are widely used in many fields such as nanospheres, nanofibers, scaffolds etc. 
(Figure 1.8).
33 
Nanotechnology is widely used in material sciences and has a wide application in many areas 
including medicine and pharmacy and as a result three important definitions should be 
considered; 
(i) Nanoscience: it is the science that deals with manipulation of materials at the molecular and 
atomic scales. 
(ii) Nanomedicine: it is the use of particles < 1 µm in size to treat, diagnose and control the 
biological systems. 
(iii) Pharmaceutical Nanotechnology: it is the use of nanomaterials in pharmaceutical fields such 
as drug delivery systems, diagnostic agents and biosensors. Numerous studies in this field have 
illustrated revolutionary results in the diagnosis and treatment of many fatal diseases such as 
cancer, bacterial infections and diabetes mellitus.
34
 
 
Figure 1.8 Different forms of nanomaterials such as Nanospheres (a-b). Nanofibres (c-d). Foams 
(e-f). Knitted textiles (g-i). Selective laser sintered scaffold (j-o). Fused deposition modelled 
scaffolds (p–u). 33 
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The unique properties of nanomaterials compared to their bulk counterparts are mainly due to the 
unique physical and chemical properties of the matter in the nano-form which differ completely 
from the original bulk form. This is due to the fact that the materials in the nano-form are very 
small in size and as a result, the surface area of the nanomaterials increases leading to a 
noticeable change in the thermodynamic characteristics of the nanomaterials and the kinetics of 
the chemical reaction of these nanomaterials become specific. Furthermore, a marked 
improvement in the bioavailability and solubility of the the nano-form structures was observed.
35
 
The differences between the nanoparticles and that in the bulk form are summarized in Table 1.3.  
Table 1.3 The main differences between bulk and nano-forms. 
(34-38) 
 Bulk form Nano-form 
1-Surface/volume ratio Lower Higher 
2-Surface area Smaller Larger 
3-Solubility and dispersion 
in the media 
Lower Higher 
4-Bioavailability and 
efficiency 
Lower Higher 
5-Therapeutic doses Needs higher doses to attain 
their therapeutic actions. 
Needs lower doses to attain 
their therapeutic actions. 
6-Onset of action Slow Rapid 
7- Duration of action Low or intermediate action Higher duration (sustained 
release) 
8-Side effects high Dependent on the particle 
size and surface charge. 
 
On the other hand, nanoparticles (NPs) might suffer larger adverse effects than the particles in 
the bulk form such as toxicity. This toxic effect of the NPs is dependent on the type of the 
composition of the particles and the dispersion of the NPs in different media as the surrounding 
environments can stimulate or inhibit certain toxicities. Nano-toxicity might be attributed to the 
high surface/volume ratio of the NPs relative to the bulk form. As a result, as the surface/volume 
16 
 
ratio increases, the physicochemical, electrical, reactivity and optical properties are highly 
manipulated.
36, 37
 For instance, it was found that the nano-size of polystyrene NPs affects its 
toxicity where polystyrene NPs with sizes of 60 nm and negative surface charges have more 
toxic effects on blood than the same material with larger sizes. In addition, polystyrene NPs with 
sizes around 20 nm were found to increase hemolytic effect on red blood cells (RBCs). As a 
consequence, both surface charge and particle size should be considered when investigating the 
toxicity of different NPs.
36
 In addition, NPs might have toxic effects on gastrointestinal, 
respiratory and cardiovascular systems. For instance, Carbon Nanotubes (CNTs) were found to 
cause lung inflammation and necrosis in mice more than carbon black or quartz.
38
 On the other 
hand, fullurenes were found to be safer than CNTs because the latter were found to increase 
platelet aggregation.
 38
 
1.3.1 Nanomaterials and Targeted Drug Delivery systems (TDDS) 
TDDS has attracted great interest in research nowadays because they increase the concentrations 
of the drugs inside the specific organs and decrease their concentrations in the other organs in an 
independent manner from route and method of drug administration. Besides, they deliver drugs 
to the targeted organs at controlled release kinetics causing the time of action to be extended 
inside the body and at the same time, they enhance the selectivity of binding of the targeted drug 
to its receptor at a molecular level which will increase the efficiency and will reduce the adverse 
effects.  
Nanotechnology plays an important role in the TDDS and many types of Nano-carriers are 
involved in the TDDS such as CNTs, Fullurenes, Liposomes and polymeric Nano-composites 
More than 1000 Nano-pharmaceutical patents have been approved by the U.S patent and 
trademark office during the years 1999-2008. 
39, 40
 
As a result, when drugs are loaded on Nano-carriers, this offers huge benefits such as improving 
the solubility of the hydrophobic agents which in turns will improve their bioavailability, bio-
distribution, and their ability to be given by intra-venous route, increasing the permeability of 
drugs to the blood brain barrier and finally, decreasing the hypersensitivity allergic reactions by 
delivering the drug to the target site. 
40, 41
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The mechanism by which the nano-carriers deliver drugs to the targeted organs is achieved by 
adhering to the cell membrane and then, entering the cell by endocytosis where the nano-carriers 
undergo lysosomal degradation where the drug is released freely inside the cytoplasm of the 
targeted organ and the nano-carriers are then removed from the cells by exocytosis (Figure 
1.9).
42
 
 
Figure1.9 A schematic representation of the mechanism of cellular targeting of the Nano-
carriers containing drugs.
42
  
1.3.2 Polymeric Nano-composites (PNCs) 
Polymer nanocomposites (PNCs) are composed of polymeric matrix reinforced with a filler 
material whose size is at the nanoscale. A wide variety of PNCs have been reported with superior 
properties compared to the parent materials. PNCs have been used in a wide variety of 
applications across various disciplines such as plastics, food packaging, biomedical and 
environmental applications. PNCs have widely been used in TDDS specially due to the 
capability of PNCs to either capture the drugs within their structures (encapsulation) or bearing 
the drugs on the polymeric surface structures (surface decoration). PNCs can be classified as 
either nano-spheres or nano-capsules. Nano-spheres are matrix-like structure formed by 
dispersing the drug through the polymeric matrices, while nano-capsules are formed by loading 
the drug within a cavity or inner core surrounded by a polymeric membrane, but also drug can be 
adsorbed on the polymer surface (Figure 1.10). 
34, 39
 
This, in turn, increases the stability of the drugs, as well as extends their half -lives and more 
importantly they will be well-targeted to the organs of interest. In addition, PNCs have many 
other advantages such as increasing the stability of volatile drugs, modifying the drug release 
18 
 
which will help in the delivery of vaccines, anticancers and antibiotics and finally, PNCs can 
play an important role in tissue engineering and antibacterial scaffolds.  
 
Figure 1.10 A schematic illustration showing the difference between nano-spheres and nano 
capsules.
39
 
It is worth mentioning that polymers that are used in PNCs should satisfy some requirements 
such as biocompatibility, biodegradability and to be FDA approved (especially for applications 
that are directly related to human contacts). Polymers used are either natural such as starch, 
cyclo-dextrin, alginate, chitosan, gum acacia and gelatin or synthetic such as polylactides (PLA), 
polyglycolides (PLG), Polyethylene glycols (PEG), poly(lactic-co-glycolic) (PLGA) and poly 
carpactolactone (PCL).  
When using PNCs in TDDS, drugs are released from the polymeric carrier through three main 
physicochemical mechanisms where (i) either the drug is dissociated from the polymeric matrix 
or (ii) the polymer NPs undergo swelling by hydration followed by diffusion of the drug outside 
the polymeric matrix or finally, (iii) the polymer might suffer from enzymatic reaction at the site 
of the delivery resulting in the cleavage of the polymer and the release of the drug to the desired 
site. 
34, 39, 43, 44
  
Many methods are involved in the preparation of polymeric NPs particularly those prepared from 
synthetic polymers, but the most interesting methods are the top-down techniques (e.g. 
dispersion of the preformed polymers) where the NPs are synthesized from preformed polymers 
(synthetic polymers dissolved in organic solvent). This method can be accomplished through 
four different techniques which are: (i) nanoprecipitation (solvent displacement), (ii) 
emulsification/solvent evaporation, (iii) emulsification/solvent diffusion and (iv) salting out, as 
will be described below. 
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(i) Nanoprecipitation (solvent displacement) 
This method is normally carried out either in the presence or absence of a surfactant molecule. In 
this method, the preformed polymer is precipitated from organic solution, thereafter; the organic 
solvent is diffused in aqueous medium. Briefly, this method is carried out by dissolving the 
synthetic polymer in a solvent of intermediate polarity and water miscibility such as acetone, 
acetonitrile or ethanol. Then, this organic phase is injected in distilled water with or without a 
stabilizer (surfactant) during magnetic stirring leading to fast diffusion of the organic solvent into 
the aqueous medium with instantaneous formation of colloidal suspension (Figure1.11). Then, 
the solvent is removed under vacuum pressure. 
(44- 48)
 
This method is applicable to hydrophobic drugs, but not efficient for water soluble drugs and it is 
applicable to a wide range of synthetic polymers such as PLGA, PLA, PCL, etc 
(44- 48)
.
 
This method was reported to be successful in the incorporation of cyclosporine with entrapment 
efficiencies up to 98%. 
49
 
Nanoprecipitation technique has many advantages including the involvement of non-toxic 
solvents, reduction of energy consumption as it needs regular stirring only not high shear stress, 
and additives can be used to decrease the size of the NPs. On the other hand, this method has 
some drawbacks such as the drugs prepared by this method should be highly soluble in polar 
solvents and slightly soluble in water, hydrophilic drugs weakly interact with the polymer 
leading to low loading efficiency and finally, this method is time consuming as solvent should be 
removed by evaporation. 
48
 
 
Figure 1.11 A schematic representation of the nanoprecipitation technique.
44
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(ii) Emulsion/solvent evaporation method (ESE) 
This method involves solubilizing the polymer in organic solvent that is immiscible in water 
such as chloroform, dichloromethane or ethyl acetate. The organic phase is then added to an 
aqueous solution containing stabilizer while applying a high shear stress by using either high 
speed homogenizer or probe utra-sonicator forming an emulsion. Then, the solvent is evaporated, 
by magnetic stirring at room temperature or under reduced pressure, in order to obtain the NPs 
from the emulsion. Finally, polymer NPs are collected by ultra-centrifugation, washed several 
times with distilled water and then, lyophilized (Figure 1.12).
 (44- 48) 
 
This method was reported to be useful for both hydrophobic drugs (single O/W emulsion) and 
hydrophilic drugs (double W/O/W emulsion). 
Moreover, this method was reported to give rise to a wide range of nano-sizes because the nano-
sizes are dependent on the type of organic solvent, homogenization and/or stirring rates, types 
and amounts of surfactants, molecular weight and concentration of the polymer involved and 
also the temperature. 
The advantages of this method include the use of a wide variety of solvents, suitable for both 
hydrophilic and hydrophobic drugs, in addition to using additives to decrease the sizes of NPs. 
On the other hand, this method involves the use of high energy stress leading to high energy 
consumption, and solvent evaporation leads to time consumption and finally, the addition of any 
active ingredient affects the final size of NPs.
 (44- 48)
 
 
 Figure 1.12 A schematic representation of emulsification/solvent evaporation method.
46
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(iii) Emulsification/solvent diffusion method (ESD) 
It is similar to Emulsification/solvent evaporation technique mentioned earlier, but with some 
modifications. 
In brief, the polymer is dissolved in a solvent which is partially miscible in water such as 
propylene carbonate and then, saturated with water to ensure the initial thermodynamic 
equilibrium of the two liquids. Diffusion of the solvent of the dispersed phase should be 
promoted by dilution with excess amounts of distilled water in order to precipitate the polymer 
and obtain polymer NPs. Then, the polymer dissolved in the solvent saturated with water is 
emulsified in an external aqueous phase containing surfactant resulting in diffusion of the solvent 
to the external phase with the formation of polymer NPs. Finally, the solvent is removed by 
filtration or evaporation (Figure 1.13).
 (44- 48) 
The advantages of this method include simplicity, no need to external shear stress, narrow size 
distribution of the polymer particles and high encapsulation efficiencies. On the other hand, this 
method suffers from the need to eliminate high volumes of water and the loss of hydrophilic 
drugs into the external aqueous phase.
 (44- 48) 
 
 
 
Figure1.13 A schematic representation of Evaporation/solvent diffusion method.
44
 
 
The three methods mentioned earlier are summarized in Figure 1.14. 
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Figure 1.14 A schematic representation summarizing nanoprecipitation, ESE and ESD 
methods.
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(iv) Salting out method 
Salting out is carried out in solutions of high ionic strength that reduce the solubility of the 
molecules causing the polymer and drug to precipitate. As a result, salting out effect is used to 
separate a water miscible solvent from aqueous solution. Salting out method is considered as a 
modification to ESD method where both the drug and the polymer are dissolved in a specific 
solvent such as acetone and then, emulsified into an aqueous phase which contains colloidal 
stabilizer such as polyvinylpyrrolidone (PVP) and a salting out agent in order to increase the 
ionic strength of the solution. The salting out agents are either non-electrolytes such as sucrose or 
electrolytes such as calcium chloride, magnesium chloride and magnesium acetate. Then, 
dilution with excess water is carried out to increase the diffusion of acetone into the aqueous 
phase leading to the formation of nanospheres and finally, the salting out agent and the solvent 
are removed by cross-flow filtration (Figure 1.15).
  (44- 48)
 
The advantages of this method include its suitability to heat sensitive drugs as it does not require 
increasing temperature and it is very suitable for proteins as it has minimum stress on proteins. 
On the other hand, it is not suitable to hydrophobic drugs and needs several washing steps to the 
NPs.
 (44- 48) 
23 
 
 
Figure 1.15 A schematic representation of the salting out method.
44
 
There are many types of synthetic polymers that are approved to be used by FDA as mentioned 
earlier, but PLGA and PEG are of great interest for this thesis because of their biocompatibility, 
efficiency in drug delivery and approval to be used in drug delivery by FDA and will be 
discussed in the following sections in more details. 
The four methods used in the preparation of polymeric NPs are summarized in Table 1.4 where 
the type of drug, energy consumption, time consumption and type of solvent for each method is 
presented. 
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Table 1.4 A comparison between the four methods used in the preparation of polymeric NPs. 
 Nanoprecipitation ESE ESD Salting out 
1-Type of drug Hydrophobic drugs Hydrophobic & 
hydrophilic 
drugs 
Better 
hydrophobic 
drugs. 
Hydrophilic 
drugs. 
2-Energy 
consumption 
Reduced energy 
consumption as it 
needs regular 
stirring only not 
high shear stress. 
High energy 
consumption 
due to the use of 
high energy 
stress. 
Reduced energy 
consumption as 
it needs regular 
stirring only not 
high shear 
stress. 
Reduced energy 
consumption as 
no shear stress. 
3-Time 
consumption 
Time consuming as 
solvent should be 
removed by 
evaporation. 
Time consuming 
as solvent 
should be 
removed by 
evaporation 
Time consuming 
as high volumes 
of water should 
be eliminated 
Time consuming 
as it needs 
several washing 
steps in order to 
remove the 
salting out agent. 
4-Type of 
solvent 
Water miscible 
solvents such as 
acetone, acetonitrile 
or alcohol. 
Water 
immiscible 
solvents such as 
chloroform, 
DCM or ethyl 
acetate. 
Partially 
miscible in 
water such as 
propylene 
carbonate. 
Acetone. 
 
1.4   Poly lactic-co-glycolic acid (PLGA) 
PLGA is one of the promising polyester polymers that have a wide range of applications in 
biomedical, pharmaceutical and tissue engineering fields because of its biocompatibility, 
biodegradability and approval to be used in drug delivery by FDA. 
50 
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1.4.1 Synthesis of PLGA 
PLGA is a linear, aliphatic and amorphous polyester co-polymer that is synthesized from the 
polymerization of two monomers which are glycolic acid and lactic acid. During polymerization, 
several monomeric units of glycolic or lactic acids are linked together by ester linkages in the 
presence of tin (II) 2-ethylhexanoate, tin (II) alkoxides and aluminum isopropoxide as catalysts.
51
 
PLGA has many forms such as PLGA 50:50, PLGA 75:25, PLGA 65:35 etc. and this is 
dependent on the ratio of monomers that are used during synthesis (Figure 1.16).
51, 52
 
                                            
Figure 1.16 The chemical structure of PLGA where (x) is the number of lactic acid units and (y) 
is the number of glycolic acid units.
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1.4.2 Biodegradation of PLGA 
 Biodegradation is an important step in order to release the drug incorporated on the PLGA 
surface inside the body. 
It is the hydrolytic degradation of PLGA co-polymer inside the body in presence of water 
through the cleavage of its ester linkages producing glycolic acid and lactic acid which are 
byproducts of different metabolic pathways inside the body (Figure 1.17). The formed 
byproducts are easily metabolized and eliminated from the body through Kreb’s cycle (metabolic 
pathway inside the living cells which is the aerobic metabolism of carbohydrates, proteins and 
fatty acid forming ATP) and as a result, PLGA is considered as a safe polymer with minimum 
toxicity in drug delivery systems.
50, 51
 
The degree of PLGA biodegradation is dependent on the monomer ratio involved during its 
synthesis. As a consequence, PLGA 50:50 is hydrolyzed much faster than PLGA 65:35 which is 
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hydrolyzed much faster than PLGA 75:25 and PLGA 75:25 is hydrolyzed faster than PLGA 
85:15.
51, 52, 53, 54, 55, 56, 58
 
 
 Figure 1.17 The hydrolysis of PLGA.
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1.5 Poly ethylene glycol (PEG) 
PEG is hydrophilic, non-ionic polyether that is synthesized by polymerization of several ethylene 
glycol monomers forming PEG of different molecular weights (Figure 1.18). Unlike PLGA, PEG 
does not undergo biodegradation inside the body as it is excreted in an unchanged form in urine. 
On the other hand, PEG does not accumulate inside the body organs and it is very biocompatible 
and as a result, it can be used successfully in drug delivery.
59
 
Because of its high water solubility, the addition of PEG to other hydrophobic polymers such as 
PLGA during polymer NPs preparation offers many advantages as described below: 
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a- PEG increases the solubility of polymer NPs and the hydrophobic drugs incorporated 
inside it. 
b- PEG increases the stability of polymer NPs in aqueous media (proved by increasing the 
zeta potential readings) which enables them to be stored for a long period of time. 
c- PEG prevents the aggregation of polymer NPs by its steric hindrance effect and as a 
consequence, decreases the nano-size.  
d- Upon coating the nano-carriers with PEG, it plays an important role in suppressing the 
opsonization phenomenon (hiding the NPs from the immune system thus preventing their 
elimination by the bloodstream). As a consequence, it increases the in-vivo circulation 
time of drugs inside the body, thus increasing the probability that the drugs reach their 
site of action and this is known as stealth effect. 
e- PEG has no interaction with the charged biological molecules inside the body such as 
DNA because it does not involve any ionic moieties.  
f- PEG increases the permeability and release of the drugs from the NPs.   
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Figure 1.18 The chemical structure of PEG.
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Chapter 2: Materials and Methods 
2.1 Materials 
All chemicals were of analytical grade and used as received from the source without any further 
purification. 50/50 D –Lactide/Glycolide co-polymer 0.2 dL/g (Purasorb PDLG) was purchased 
from Purac Biochem, Gorinchem  (The Netherlands), Poly ethylene glycol 6000 (PEG 6000) was 
purchased from Biotech Canada.  Dichloromethane (DCM), Polaxmer 407 purified non-ionic 
surfactant, Sodium Hydroxide (NaOH), Lactose, and Garlic oil blend were purchased from 
(Sigma-Aldrich, Germany). 
2.2 Methods used for preparation and characterization of the conjugated NPs 
Single emulsion/solvent evaporation (SE/SE) technique was used in the preparation of PLGA-
Garlic oil Nanoparticles (PLGA-GO-NPs) as described below: 
2.2.1 Preparation of PLGA-GO-NPs 
The method used in the preparation of PLGA-GO-NPs was adopted from a number of different 
published protocols with some modifications. 
(61- 65)
  
The detailed steps of the preparation of the different PLGA-GO-NPs samples are illustrated in 
Figure 2.1. PLGA NPs were prepared by oil/water (o/w) solvent evaporation technique which 
involved the subsequent dropwise addition of 8 mL of dichloromethane (DCM) containing 400 
mg of PLGA and 5% w/w GO (GO concentration was calculated with respect to the polymer 
weight where 5% was chosen as reported from earlier researchers) to 100 mL of 1.25% (wt/v) 
aqueous Polaxmer 407 solution which contains 2 grams of lactose, followed by homogenization 
of the mixed solution at a speed of 11,000 rpm using homogenizer (IKA T18 basic ULTRA-
TURRAX) for 5 min. The homogenization process was performed over ice bath and the resulting 
o/w nano-emulsion was stirred continuously on a magnetic stirrer at minimum speed and allowed 
to evaporate overnight. The particles were then collected by ultra-centrifugation (Ultra 
centrifuge- Hermle LaborTECHNIK GMBH) at 4 ºC at 10,000 rpm for 30 min. and washed with 
distilled water 4 times using the same centrifugation conditions mentioned earlier. The sediment 
was then re-suspended in distilled water where part of this solution was kept for particle size and 
Zeta potential determination, while the rest of the solution was freeze dried (lyophilized) at -85 
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ºC and 0.012 mbar (Labconco freeze dryer, Freezone 4.5 Plus, Labconco) for 48h. Freeze drying 
of polymeric particles included the addition of diluted solutions of the washed polymeric 
particles to 20 mL clear freeze-drying glass containers (cuvette), covered with Para-film 
perforated with 20 needle width holes, and frozen at -16 
ο 
C for 12 hours. Then, the samples were 
lyophilized for 48 hrs using the freeze dryer, under vacuum drawn by a high vacuum pump. 
Dried polymeric particles loaded with garlic oil (PLGA-GO-NPs-1) were stored at room 
temperature in a desiccator. 
(61-65) 
The same steps mentioned above were repeated twice with the 
same homogenization speed, but at homogenization time intervals of 10 min. and 15 min., 
respectively as illustrated in Figure 2.1. 
 
 
Figure 2.1. A schematic illustration of the preparation steps of PLGA-GO-NPs. 
2.2.2 Preparation of PLGA-PEG-GO-NPs 
PLGA-PEG NPs were prepared by O/W solvent evaporation technique which involved the 
subsequent dropwise addition of 8 mL of DCM containing 300 mg of PLGA, 100 mg PEG 6000 
and 5% (w/w) GO (GO conc. was calculated with respect to the polymer weight), to 100 mL of 
1.25% (w/v) aqueous Polaxmer 407 solution which contains 2 g of lactose followed by 
homogenization at a speed of 11,000 rpm using homogenizer for 5 min. Then the same steps 
(illustrated in Figure 2.1) described earlier were repeated twice with the same homogenization 
speed, but at homogenization time intervals of 10 min. and 15 min., respectively 
(61- 65)
 
2.2.3 Preparation of Mono-dispersed GO-polymer NPs 
In order to prepare GO-polymer NPs that have stable, unchanged nano-sizes and mono-dispersed 
index, the following steps (illustrated in Figure 2.2) were carried out: 
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The nano-emulsion obtained from section 2.2.1 was divided into two parts: nano-suspension 
(NS) and nano-filtrate (NF) as illustrated in Figure 2.2 in the two pathways (path I for NS and 
path II for NF) where the following steps were carried out: 
In pathway I (NS), the nano-suspension prepared at homogenization time interval of 5 min. was 
left to settle for 24hrs, the supernatant was separated and then, filtered through a biological filter 
(0.2 µm Versapor® hydrophobic membrane) forming PLGA-GO-NS-01. In path II (NF), the 
nano-emulsion was filtered through a Buchner funnel then, the filtrate was left to settle for 24hrs 
and then filtered through a biological filter (0.2 µm Versapor® hydrophobic membrane) forming 
PLGA-GO-NF-01. In order to study the effect of mechanical shaking on the NPs, vortex stirring 
for 2 min. was carried out to PLGA-GO-NF-01 forming PLGA-GO-NF-06. The steps mentioned 
above were repeated for the PLGA-GO nano-emulsions prepared at homogenization time 
intervals of 10 and 15 min. Moreover, the steps mentioned above were repeated for the PLGA-
PEG-GO nano-emulsions (section 2.2.2) prepared at homogenization time intervals of 5, 10 and 
15 min forming PLGA-PEG-GO-NS-01, PLGA-PEG-GO-NF-01 and PLGA-PEG-GO-NF-06.  
 
Figure 2.2. A schematic representation summarizing the preparation steps of each of PLGA-GO-
NFs and PLGA-PEG-GO-NFs. 
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The preparation factors of the mono-dispersed PLGA-GO NPs are summarized in Table 2.1 
where PLGA-GO-NS-01 is the nano-suspension obtained after solution settling and filtration 
through biological filter, PLGA-GO-NF-01 is the nano-suspension obtained by filtration through 
a Buchner funnel, thereafter left to settle for 24hr and then, filtered again through a biological 
filter, and PLGA-GO-NF-06 which was obtained by mechanical shaking by using vortex stirring 
of PLGA-GO-NF-01. 
Table 2.1 The preparation factors of mono-dispersed PLGA-GO NPs. 
 PLGA-GO-NS-01 PLGA-GO-NF-01 PLGA-GO-NF-06 
PLGA 
concentration (mg) 
400  400  400  
GO concentration* 
(%) 
5 5 5  
Polaxmer 407 
concentration (%) 
1.25  1.25  1.25  
Homogenization 
speed (rpm) 
11,000  11,000  11,000  
Homogenization 
Time (min.) 
5, 10 and 15  
 
5, 10 and 15  5, 10 and 15  
Buchner 
filtration** 
 
- 
 
+ 
 
+ 
Settling of the 
suspension ** 
 
+ 
 
+ 
 
+ 
Filtration through 
biological filters** 
 
+ 
 
+ 
 
+ 
Vortex stirring - - + 
* The GO content is calculated with respect to the polymer weight. 
** The (+ve) and (-ve) signs indicate the presence or absence of the specified step 
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The preparation factors of the mono-dispersed PLGA-PEG-GO NPs are summarized in Table 2.2 
where PLGA-PEG-GO-NS-01 is the nano-suspension obtained after solution settling and 
filtration through biological filter, PLGA-PEG-GO-NF-01 is the nano-suspension obtained by 
filtration through a Buchner funnel, thereafter left to settle for 24hr and then, filtered again 
through a biological filter, and PLGA-PEG-GO-NF-06 which was obtained by mechanical 
shaking by using vortex stirring of PLGA-GO-NF-01. 
Table 2.2 The preparation factors of mono-dispersed PLGA-PEG-GO NPs. 
 PLGA-PEG-GO-
NS-01 
PLGA-PEG-GO-
NF-01 
PLGA-PEG-GO-
NF-06 
PLGA concentration 
(mg) 
300  300  300  
PEG  
Concentration (mg) 
100  100  100  
GO concentration* 
(%) 
5  5 5  
Polaxmer 407 
concentration (%) 
1.25  1.25  1.25  
Homogenization 
speed (rpm) 
11,000  11,000  11,000 
Homogenization 
Time (min.) 
5, 10 and 15  
 
5, 10 and 15 5, 10 and 15  
Buchner filtration** - + + 
Settling of the 
suspension ** 
 
+ 
 
+ 
 
+ 
Filtration through 
biological filters** 
 
+ 
 
+ 
 
+ 
Vortex stirring - - + 
* The GO content is calculated with respect to the polymer weight. 
** The (+ve) and (-ve) signs indicate the presence or absence of the specified step 
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Finally, PLGA-GO-NS-01, PLGA-GO-NF-01 and PLGA-GO-NF-06 were characterized using 
PCS, Laser anemometry, SEM, FT-IR spectroscopy and UV-visible spectrophotometry. 
Furthermore, their anti-bacterial activities were investigated using Staphylococcus aureus and 
Eichercia coli (Figure 2.3).Similarly, PLGA-PEG-GO-NS-01, PLGA-PEG-GO-NF-01 and 
PLGA-PEG-GO-NF-06 were characterized using the same methods implemented with PLGA-
GO-NPs. 
 
Figure 2.3. A schematic illustration of the methods of characterization and applications of each 
of the NPs. 
 
2.2.4 Challenges during NPs preparation (poly-dispersed particles) 
During the preparation of the different GO-polymer NPs, NS-01, NF-01 and NF-06 for both 
PLGA-GO and PLGA-PEG-GO formulations (that were mentioned earlier in sections 2.2.1 and 
2.2.2) a number of factors (challenges) have been found to affect the stability and monodispersity 
of the prepared NPs and caused variations in the sizes and resulted in unstable NPs that had large 
nano-sizes and polydispersity index (PDI). According to Figure 2.4, in path I (NS), when the 
particle size of nano-emulsion PLGA-GO-NS-03 prepared from section 2.2.1 was immediately 
measured, it was observed that the sizes of the NPs were larger, unstable and had wide range of 
PDI. As a result, the steps presented in Figure 2.4 were followed (path I NS and path II NF) in an 
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attempt to overcome the challenges and obtain stable NPs with small particle sizes and narrower 
PDI. As a consequence, these challenges such as settling of the solution, filtration through 
biological filter and / or Buchner funnel and vortex stirring were found to have a pronounced 
effect on decreasing the particle sizes and having a stable NPs. As a result, the scheme presented 
earlier in Figure 2.2 was the best optimized protocol that was followed to prepare stable GO-
polymer NPs in order to overcome these challenges that are presented in Figure 2.4.  
 
 Figure 2.4. A schematic illustration of the preparation of unstable poly-dispersed particles (NS) 
that lead to the preparation of the mono-dispersed particles (NF).  
The preparation factors of the poly-dispersed NPs that were obtained during preparation of the 
stable PLGA-GO NPs are presented in Table 2.3 
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Table 2.3 The preparation factors of poly-dispersed PLGA-GO NPs. 
 PLGA-GO 
-NS-02 
PLGA-GO 
-NS-03 
PLGA-GO 
-NS-04 
PLGA-GO 
-NF-02 
PLGA-
GO 
-NF-03 
PLGA-GO 
-NF-04 
PLGA-GO 
-NF-05 
PLGA 
concentration 
(mg) 
400  400  400  400  400  400  400 
GO 
concentration* 
(%) 
5  5  5  5 5 5 5 
Polaxmer 407 
concentration  
(%) 
1.25  1.25  1.25  1.25  1.25  1.25  1.25 
Homogenization 
speed (rpm) 
11,000  11,000  11,000  11,000  11,000  11,000  11,000  
Homogenization 
Time (min.) 
5, 10 and 
15  
5, 10 and 
15  
5, 10 and 
15  
5, 10 and 
15 
5, 10 and 
15  
5, 10 and 15  5, 10 and 15  
Buchner 
filtration** 
- - - + + + + 
Settling of the 
filtrate 
solution** 
+ - - + - - + 
Filtration 
through 
biological 
filters** 
- - + - - + - 
Vortex stirring - - - - - - + 
* The GO content is calculated with respect to the polymer weight. 
** The (+ve) and (-ve) signs indicate the presence or absence of the specified step. 
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The preparation factors of the poly-dispersed NPs that were obtained during preparation of the 
stable PLGA-PEG-GO NPs are presented in Table 2.4. 
Table 2.4 The preparation factors of poly-dispersed PLGA-PEG-GO NPs. 
 PLGA-
PEG-GO 
-NS-02 
PLGA-
PEG-GO 
-NS-03 
PLGA-
PEG-GO 
-NS-04 
PLGA-
PEG-GO 
-NF-02 
PLGA-
PEG-GO 
-NF-03 
PLGA-
PEG-GO 
-NF-04 
PLGA-
PEG-GO 
-NF-05 
PLGA 
concentration (mg) 
300  300  300  300  300 300  300 
PEG 
Concentration 
(mg) 
100  100  100  100  100  100  100  
GO 
concentration* 
(%) 
5  5  5  5  5 5 5 
Polaxmer 407 
concentration (%) 
1.25  1.25  1.25  1.25  1.25  1.25  1.25 
Homogenization 
speed (rpm) 
11,000  11,000  11,000  11,000  11,000  11,000  11,000 
Homogenization 
Time (min.) 
5, 10 and 
15  
5, 10 and 
15  
5, 10 and 
15  
5, 10 and 
15. 
5, 10 and 
15  
5, 10 and 15  5, 10 and 15  
Buchner 
filtration** 
- - + + + + + 
Settling of the 
filtrate solution** 
+ - - + - - + 
Filtration through 
biological filters** 
- - - - - + - 
Vortex stirring - - - - - - + 
* The GO content is calculated with respect to the polymer weight. 
** The (+ve) and (-ve) signs indicate the presence or absence of the specified step. 
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2.3 Characterization of the pre-formed GO composite NF & NS 
The morphology, particle size, zeta potential, structural composition and optical properties of 
each of the GO composite NF and NS samples were determined using different techniques 
including scanning electron microscopy (SEM) (FESEM, Leo Supra 55 – Zeiss Inc., Germany), 
Fourier Transform Infrared (FT-IR) (Nicolet 380-Thermo Scientific), Photon correlation 
spectroscopy (using Malvern zeta-sizer nano-series (ZS 90), UK) and Ultraviolet–Visible (UV-
Visible) spectroscopy (CARY 500 UV–Visible Spectrophotometer). 
2.3.1 Determination of GO composite NF & NS size using Photon correlation spectroscopy 
(PCS) 
Photon correlation spectroscopy (PCS) technique is sometimes referred to as dynamic light 
scattering (DLS)or Quasi-Elastic light scattering, and it is involved in the measurement of the 
sizes of particles suspended in a liquid solution. PCS is beneficial in the determination of the 
NPs sizes in the range of 3-1000 nm. DLS is widely used for detecting the sizes and shapes of 
different NPs. PCS is based on the production of an oscillating polarization on the NPs surface 
inside the liquid sample by the electric field of the incident light (laser), and this incident light is 
scattered by the NPs whose polarity differs from the solvent surrounding them. DLS is composed 
of laser light source (HeNe), sample chamber at which two laser beams intersect, two bragg cells 
and a beam splitter (Figure 2.5).
66
 The NPs in the solution are in constant motion known as 
Brownian motion, which is defined as the random movement of particles due to bombardment by 
the solvent around it. This motion causes fluctuations in the detected intensity signal that can be 
detected digitally by PCS. The duration of the fluctuations results in the size and the 
polydispersity index of the measured NPs. 
66, 67
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Figure 2.5. A schematic representation of DLS spectroscopy. 
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2.3.1.1 Sample preparation for particle size and zeta-potential measurements 
PLGA-GO-NPs and PLGA-PEG-GO-NPs suspensions were prepared by dispersing 10 mg of the 
suspension in 5 mL distilled water, then 0.3 mL of the suspension were dispersed in 2 to 3 mL of 
0.22 µm filtered distilled water, and their size was measured with regards to the polydispersity 
and Z-average diameter which is the NPs average size in nm. 
67 
Zeta potential of the PLGA-GO-NPs and PLGA-PEG-GO-NPs were determined in millivolts 
(mV) by laser anemometry where the surface charge of the NPs in solution was determined.
68
 
PLGA-GO-NPs and PLGA-PEG-GO-NPs suspensions were prepared by dispersing 5 mg of the 
suspension in 1- 2 mL distilled water, and then 0.5 mL of the suspension was diluted in 0.001 M 
KCl solution, which acts as a weak electrolyte, to get a sample of appropriate concentration for 
the measurement. 
2.3.2 Measurement of the zeta-potential of the GO composite NF & NS using Laser 
anemometry 
Zeta-potential is a physical property on any particle suspended in a solution and it is important in 
detecting the long-term stability of the NPs. As the particles have a great positive or negative 
zeta potential, the particles will tend to repel each other and as a result, the stability of the 
suspended particles will increase and the tendency of the particles to aggregate will decrease.  
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2.3.3 Scanning Electron Microscopy (SEM) 
SEM is an electronic technique with high resolution and large depth of field that is able to 
characterize the surface morphology of different organic and inorganic materials on a scale of 
nanometer (nm) to a micrometer (µm). SEM consists of two major components which are 
microscope column (that contains electron gun, electron lenses, specimen stage and X-ray 
detector) and control console (that contains cathode ray tube, viewing screen and computer 
keyboard). Samples were placed in the specimen chamber under vacuum where the electron gun 
focused on the sample using objective lens (which had the function of focusing the electron 
beam before it falls on the specimen surface) and started generating electrons and accelerating 
them. When the beam of electrons bombarded the sample surface, a secondary electron beam 
was produced which was then collected by the detector where voltage signal, needed to produce 
image in the cathode ray tube, was generated (Figure 2.6).
69, 70 
                            
A thin layer of nano/microparticles was spread on a circular aluminum plate using a carbon disc 
and the surface was then coated with a gold film using a sputter coater under an Argon 
atmosphere. Nano/microparticles were identified by magnification with SEM (FESEM, LEO 
Supra 55-Zeiss Inc., Germany). 
 
Figure 2.6. A schematic representation of SEM. 
70
 
41 
 
2.3.4 Fourier Transform Infrared (FT-IR) Spectroscopy 
FT-IR spectroscopy is used in characterizing the chemical structures of samples and the presence 
of functional groups. FT-IR spectroscopy is used in analyzing many different signals into their 
constituent frequency components at which different frequencies components are simultaneously 
determined in one single operation by the use of certain computational mathematical treatments. 
FT-IR spectroscopy can be also known as interferometry or time-domain spectroscopy. This 
technique increases the sensitivity of the traditional spectroscopic methods of structure 
determination by 10-100 folds.
71
 
The traditional spectroscopic methods depend on the dispersion of light using prisms or gratings. 
On the other hand, FT-IR spectroscopy involves the interference of light, unlike dispersive 
methods, using specific interferometers. The traditional dispersive methods used to measure the 
optical spectra depend on passing a beam of radiation through a source into the sample where 
part of the radiation is absorbed, and the remaining radiation will be emitted and passed through 
a Monochromator (which is composed of either grating or prism). The Monochromator will 
disperse the radiation into (n) number of spectral elements, and then, the emerged beam of 
radiation will enter a detector which is sensitive to the intensity of radiation falling onto it where 
the (n) elements will be measured one by one. The dispersive methods are time consuming and 
the spectral measurements are controlled by the resolution of the Monochromator, and as a 
result, the FT-IR spectrometer involving the interference method has been developed through the 
use of Michelson Interferometer (Figure 2.7) as it is much faster.  
Michelson interferometer is composed of three major parts which are: fixed mirror, movable 
mirror and beam splitter. 
(71-73)
 The beam splitter divides the radiation beam into two beams 
where they are reflected on the two mirrors, and then the beam splitter recombines the two 
beams into one beam again and sends this beam to the detector. If the fixed and movable mirrors 
are at the same distance from the beam splitter, there will be no optical path difference (o.p.d) 
between the two beams. On the other hand, if the movable mirror moves away, there will be an 
optical path difference between the two beams (retardation). Because the path that one beam 
travels is a fixed length and the other is constantly changing as its mirror moves, the signal which 
exits the interferometer is the result of these two beams interfering with each other and the 
resulting signal is called an interferogram. 
(71-75) 
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 Figure 2.7. A schematic representation of Michelson Interferometer. 
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FT-IR spectrometer (Figure 2.8) is composed of three main parts; three optical inputs which are 
(i) He-Ne laser, (ii) white light and (iii) IR source, and the later might be mercury lamp for far IR 
or glowers for near IR, in addition to Michelson interferometer, and a detector which was 
designed in order to measure interferogram signals. When IR light hits the sample, each 
functional group within the sample absorbs a frequency of adequate photon energy which excites 
it to a higher vibrational state and thus providing fingerprint information about the chemical 
composition of the material and then, Fourier transformations took place using computer 
software. FT-IR spectroscopy produces a higher signal-to-noise ratio for a standard scan-time. 
71, 
75, 76 
 
Figure 2.8. A schematic representation of FT-IR spectrophotometers. 
76 
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The FT-IR spectra of the samples (The samples were prepared into KBr pellets) were obtained 
using a spectrophotometer in the 4000-400 cm
-1
 range (Nicolet 380-Thermo Scientific).  
2.3.5 UV-Visible (UV-vis) Absorption Spectroscopy 
This technique was involved in the construction of GO calibration curve which was further used 
in the determination of the GO% present in PLGA-GO-NPs and PLGA-PEG-GO-NPs. UV-
Visible spectroscopy is a cheap, rapid and simple technique and is composed of a light source 
(with wavelengths ranges from 200-1000nm such as xenon arc lamp), a monochromator, two 
cuvettes (one for the blank and the other for the reference), detector and read out.
17
 The radiation 
produced by the light source was passed through a beam splitter (chopper) in order to be split 
into two identical beams, which are passed through the reference and the sample alternatively. 
Then, both beams were transmitted and collected inside the detector and the absorption spectrum 
curve was then constructed by the instrument software after subtracting the reference (Figure 
2.9) 
77 
The intensity and spectral peaks of each PLGA-GO-NPs and PLGA-PEG-GO-NPs was 
measured by UV–vis spectroscopy (CARY 500 UV–visible Spectrophotometer) with a 1-cm 
quartz cell in the wavelength range (300-700) nm. 
 
Figure 2.9. A schematic representation of UV-vis spectrophotometer. 
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2. 3.6 Determination of GO % in the NPs 
The determination of the GO % in the NPs was determined according the protocol described by 
Wang et al. with slight modifications.
79
 In brief, 5.0 mg of GO was dissolved into 50 mL 
absolute ethanol to form the stock solution which was scanned by UV-vis spectrophotometer and 
the absorbance was found to be at wavelength of 217 nm. Then, a serial dilution was performed 
by taking 1, 2, 3, 4, 5 and 6 mL out of the stock solution and the volume was completed up to 25 
mL with absolute ethanol in each solution. The spectroscopic characteristics of these samples 
solutions were measured by the UV-vis spectrophotometer fixing the wavelegth at 217 nm. A 
calibration curve for the standard GO was constructed by plotting the absorbance on the Y- axis 
versus the concentration of the samples solutions on the X- axis.
79 
 
The same protocol described by Corrigan et al. was used to determine GO % in the PLGA-GO 
and PLGA-PEG-GO composites with some modifications.
80
 In brief, 5 mg  of the dried garlic 
NS (for NS-01 to NS-06), samples were suspended in 1 mL of 1 M NaOH at 37 °C overnight for 
digesting the polymer. The suspension was then centrifuged and 1 mL of the supernatant was 
taken out and completed to 25 mL with absolute ethanol (dilution factor) and then, inserted in the 
UV-vis spectrophotometer in order to determine the GO % in the GO NPs using the calibration 
curve mentioned earlier. 
1 mL of the garlic NF (for NF-01 to NF-06) were suspended in 0.2 mL 1 M NaOH and also, 
incubated at 37 °C overnight for digesting the polymer. The same steps mentioned above were 
followed for determining  GO % in the garlic NF. 
80 
2.3.7. Antibacterial activities of GO composite NS & NF 
The antibacterial activities of GO composite NS & NF were tested according to the following 
protocol:  
Preparation of Bacterial Solution  
Two kinds of bacterial strains were selected for the antibacterial tests E. coli (ATCC 8739) as a 
Gram-negative bacterium, and S. aureus (ATCC 6538) as a Gram-positive bacterium. Both 
bacteria were prepared by liquid culture, in which the desired bacteria were suspended in BD® 
DifcoTM Nutrient Broth.  
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This liquid broth consists of approximately 3g beef extract and 5g peptone per liter. After 
inoculation, the liquid broth with bacteria was grown overnight in a shaking incubator (ZHWY-
2102, SHANGAI ZHICHENG®, China) at a constant temperature of 37°C. The bacterial media 
was then diluted with nutrient broth to an optical density (OD) of 0.002 as measured using a 
spectrophotometer (T80 PG Instruments Limited, China) at a wavelength of 600 nm. 
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Antibacterial Activity Using Colony Counting Method (CCM) 
Samples to be tested for antibacterial activity were evaluated using Colony Counting Method 
(CCM) that consisted of four steps as shown in Figure 2.10. 
 
Figure 2.10. A schematic represention showing the steps that were involved in CCM. 
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First, 1 mL of inoculated bacterial solution was added to 19 mL of nutrient broth. Samples were 
then placed into the solution and incubated for 30 min. with mechanical shaking at 37°C. 
Samples lacking the active ingredient (empty vehicle PEG, PLGA, PEG+PLGA) were used as a 
control.  
Next, the incubated solution was serially diluted with de-ionized water (DI water) to obtain a 
countable number of colonies, and 10 μL of each diluted solution was spread onto the surface of 
87 × 15 mm petri dishes containing 15 mL of nutrient agar.
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The plates were then cultivated in an incubator at 37°C for approximately 24 hrs, after which the 
number of colony forming units (CFUs) per sample were determined by counting the number of 
colonies. 
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The results of each experimental were averaged from a dozen replications. Antibacterial activity 
as based on the CCM (ηCCM) was calculated by equation 2.1 as follows: 81   
                                   ………equation 2.1 81                                                      
where the superscript ‘*’ indicates the control case (bacterial concentration with buffer only). 
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Results and Discussion: 
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of PLGA-GO-NPs 
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Chapter 3: Results & discussion 
The results are divided into three subsections: section (I) for the PLGA-GO-NPs, section (II) for 
the PLGA-PEG-GO-NPs and section (III) for the anti-bacterial activities of PLGA-GO & PLGA-
GO-PEG-NSs & NFs against E. coli and S. aureus.  
3.I. Synthesis and Characterization of PLGA-GO-NPs 
The SE/SE method were chosen because it offers many advantages such as wide size ranges, 
suitable for both hydrophilic and hydrophobic drugs and wide variety of solvents can be used. 
This section will focus on the morphological examination (by SEM) and chemical structural 
characteristics (by FT-IR and UV-Vis spectrophotometry) as well as particle size, zeta potential 
and poly dipsersity index (PDI) of PLGA-GO-NPs that were prepared by the (SE/SE) technique 
using homogenization with three different homogenization time intervals (5, 10 and 15 min.) at 
the same homogenization speed of 11,000 rpm. The GO % in the NPs was also determined and 
the antibacterial evaluation of the conjugated NPs was evaluated against E. coli and S. aureus. 
The results described in this chapter are mainly focused on the nano- suspension (NS) that was 
formed after centrifugation and it is denoted by the abbreviation PLGA-GO-NS and the nano- 
filtrate (NF) solution that was formed after filtration by using Buchner funnel and it is denoted 
by the abbreviation PLGA-GO-NF, as described in Figures 2.2 & 2.4 mentioned earlier in 
chapter 2 sections 2.2.3 and 2.2.4, respectively. 
We are going to focus on the mono-dispersed NPs and the results of the poly-dispersed NPs will 
be presented in section 3.I.2. 
3.I.1 Mono-dispersed PLGA-GO-NPs 
The physicochemical properties of mono-dispersed PLGA NPs conjugated with GO that were 
prepared at three different homogenization time intervals (5, 10 and 15 min.) were compared. It 
has been reported that the size of many polyester NPs was affected by many factors such as the 
amount of the loaded drug, polymer/surfactant ratio, M.wt. of the polymer, and the method of 
NPs preparation.
(82-84)
 In this regard, all the preparation parameters (such as the concentration of 
PLGA, concentration of GO, amounts of the stabilizing agent and homogenization speed) were 
kept constant to identify the effect of the homogenization time on the physicochemical properties 
49 
 
of the mono-dispersed PLGA-GO NPs. In addition, the effect of other factors such as the effect 
of solution settling, the use of Buchner funnel in solution filtration, the use of biological filters in 
solution filtration and the effect of mechanical shaking of the solutions by using vortex stirring 
on the PLGA-GO NPs preparation were carefully examined, as mentioned earlier in chapter 2 
section 2.2.3.  
3.I.1.1 Particle size, PDI and Zeta- potential of the different mono-dispersed  PLGA-GO-
NPs 
The particle sizes, PDI and zeta potential of the different mono-dispersed PLGA-GO-NPs are 
summarized in Table 3.I.1. The particle sizes and zeta-potential of bulk GO and PLGA were 
recorded in order to evaluate the impact of the SE/SE technique on the size of PLGA and GO 
particles. 
From Table 3.I.1, one can see that the size of PLGA-GO particles have decreased by more than 
100 folds from the original size of the PLGA and GO bulk samples. 
Table 3.I.1. The particle size ranges, PDI and zeta-potential of GO, PLGA, PLGA-GO-NS-01, 
PLGA-GO-NF-01 and PLGA-GO-NF-06. 
Loaded 
polymer 
Homogenization 
time 
(min.) 
Particle size 
range (nm) 
Poly-
dispersity 
Index ± s.d 
Zeta-potential mV ± s.d 
GO (bulk) - 3508-3700 0.44 ± 0.17 -0.04 ±  0.01 
PLGA (bulk) - 2900-2945 0.48 ± 0.03 -0.23 ± 0.02 
PLGA-GO-
NS-01 
5  215-276 0.10 ± 0.06  
           -33.69 ± 3.35 10  254-294 0.22 ± 0.06 
15  245-319 0.36 ± 0.11 
PLGA-GO-
NF-01 
5  201-219 0.12 ± 0.09  
 
 
          -35.37 ± 4.62 
 
10  214-223 0.18 ± 0.09 
15  221-248 0.19 ± 0.15 
PLGA-GO-
NF-06 
5  201-213 0.16 ± 0.03 
10  219-223 0.07 ± 0.03 
15  224-230 0.11 ± 0.04 
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The particle size distribution histograms for PLGA-GO-NS-01, PLGA-GO-NF-01 and PLGA-
GO-NF-06 obtained at different homogenization times (5, 10 and 15 min.) are illustrated in 
Figures 3.I.1. 
 
Figure 3.I.1. The particle size distribution for PLGA-GO-NS-01 (a, b, c), NF-01 (d, e, f), NF-06 
(g, h, i) prepared at homogenization time intervals of 5, 10 and 15 min., respectively. 
Figure 3.I.1 shows that the particle size distributions for the nano-suspension PLGA-GO-NS-01 
prepared at 5 min. homogenization time (a) ranges from 215 nm to 276 nm, at 10 min. 
homogenization time (b) ranges from 254 nm to 294 nm and for that prepared at 15 min. 
homogenization time (c) ranges from 245 nm to 319 nm. 
Figure 3.I.1 shows that the particle size distributions for the nano-filtrate solution PLGA-GO-
NF-01 prepared at 5 min. homogenization time (d) ranges from 201 nm to 219 nm, at 10 min. 
homogenization time (e) ranges from 214 nm to 223 nm and for that prepared at 15 min. 
homogenization time (f) ranges from 221 nm to 248 nm. 
Figure 3.I.1 shows that the particle size distributions for the nano-filtrate solution PLGA-GO-
NF-06 prepared at 5 min. homogenization time (g) ranges from 201 nm to 213 nm, at 10 min. 
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homogenization time (h) ranges from 219 nm to 223 nm and for that prepared at 15 min. 
homogenization time (i) ranges from 224 nm to 230 nm. 
According to Table 3.I.1 and Figure 3.I.1, it is obvious that the SE/SE technique decreased the 
particle sizes of the bulk PLGA and GO and increased their zeta- potentials dramatically. The 
particle sizes and the PDI increased upon increasing the homogenization time from 5 to 10 to 15 
min, (at the same homogenization speed of 11,000 rpm). This could possibly be because as the 
homogenization time increases, the high shear stress of the homogenizer will result in the 
aggregation of the colloidal particles into larger ones, and thus increasing the PDI. In addition, 
PLGA might get melted by the high mechanical energy, due to the high homogenization speed, 
leading to the instability of the particles.
85
 The results revealed that the 5 min. homogenization 
time was more efficient to form NPs with smaller average particle sizes and narrower PDI and at 
the same time, it is not too long to cause the aggregation of the colloidal particles.  
Moreover, as shown in Table 3.I.1, the particle sizes and the PDI decreased when the suspension 
was left to settle followed by filtration through a biological filter. As a result, PLGA-GO-NS-01 
prepared at homogenization time 5 min. was found to have lower particle size range (215-276 
nm) and lower PDI in comparison to the NSs prepared at homogenization times of 10 and 15 
min. where they were found to have much lower average particle sizes and PDI than PLGA-GO-
NS-02, PLGA-GO-NS-03 and PLGA-GO-NS-04 that will be mentioned in the next section 
(section 3.I.2.1).  
In addition, it is noticeable that PLGA-GO-NF-01 has much smaller particle sizes in comparison 
to PLGA-GO-NS-01 formulation (Figure 3.I.2).  This is because filtration by using Buchner 
funnel removed the large particles and kept the small mono-dispersed ones resulting in 
increasing the stability and decreasing the PDI and size distribution. In addition, the effect of 
mechanical shaking the solution by using vortex stirring was studied on PLGA-GO-NF-01 
resulting in PLGA-GO-NF-06. When the size of PLGA-GO-NF-06 was compared to that of 
PLGA-GO-NF-01, it was found that vortex stirring decreased the particle sizes and PDI of 
PLGA-GO-NF-06 formulations prepared at homogenization times of 5, 10 and 15 min. This 
might be because vortex stirring separated any aggregated particles and as a result, it is 
recommended that PLGA-GO-NFs formulations should be vigorously shaken before use. 
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Furthermore, the average zeta-potential for PLGA-GO-NS-01 was found to be -33.69±3.35 
indicating the surface charges of the PLGA-GO composite NPs which limits their aggregation. 
Therefore, PLGA-GO-NS-01 achieves the highest stability and the minimum particles 
aggregation. This is attributed to the fact that as the zeta potential increases either by negative or 
positive, and this in turns indicates that the stability of the particles suspension increases and the 
particles aggregation decreases as the charged particles can repel one another.
 86, 87 
Moreover, as 
has previously been reported, the zeta potential of the polyesters NPs such as PLGA without any 
surfactant like Polaxmer 407 is high due to the presence of uncapped end carboxylic groups of 
the polyester at the NP surface which provides high negative charge.
88, 89
 Upon adding a 
surfactant to the polyester, it formed a layer on the surface of the polyester NPs that shielded the 
negative surface charge of the polyesters in an amount-dependent manner (as the amount of the 
surfactant increases, the shielding effect increases). 
89
 As a result, all the PLGA NPs were 
prepared by using Polaxmer 407 as a surfactant in constant concentration which is 1.25 %, while 
PLGA concentration was kept high (400 mg) in order to reduce the shielding effect of the 
Polaxmer for the surface negative charges of the PLGA end carboxylic groups allowing the 
PLGA-GO-NS-01 to achieve the highest negative charge of the zeta potential. In the same 
context, the excess surfactant has been removed by centrifugation at high speeds where the 
particles with average size 200-300 nm were left to sediment leaving the excess surfactant in the 
supernatant, which was then discarded, and this was found to be the most effective method for 
removing any excess surfactant in order not to alter the negative charges on the particles 
surface.
90  
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Figure 3.I.2. A comparison between the average particle sizes (nm) of PLGA-GO-NS-01, 
PLGA-GO-NF-01 and PLGA-GO-NF-06 recorded at different homogenization time intervals (5, 
10 and 15 min.). 
On the other hand, it was observed that the average zeta-potential for PLGA-GO-NF-01 and 
PLGA-GO-NF-06 was found to be -35.37 ± 4.62 which is slightly greater in negative charge 
than that of PLGA-GO-NS-01 and this might be because the filtration through a Buchner funnel 
decreased the agglomeration of the particles which caused the negative charge of the uncapped 
end carboxylic groups of PLGA to be more exposed on the surface of the particles. Therefore, 
PLGA-GO-NFs achieved the highest stability and the minimum particle aggregation. 
3.I.1.2  Morphological examination of PLGA-GO-NPs by SEM 
SEM was used to determine the shape and surface morphology of the prepared PLGA-GO 
composite NPs. SEM images of blank PLGA particles, PLGA-GO-NS-01, NF-01 and NF-06 
prepared at 5, 10 and 15 min. homogenization time intervals are illustrated in Figure 3.I.3 where 
the SEM images of NF-01 and NF-06 are the same because they were obtained from the same 
solution.  
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Figure 3.I.3. SEM images for (a) blank bulk PLGA particles, PLGA-GO-NS-01 (b, c, d), NF-01 
and NF-06 (e, f, g) prepared at homogenization time intervals of 5, 10 and 15 min. 
The SEM images of PLGA-GO-NS-01 prepared at homogenization time intervals of 5, 10 and 
15 min. are presented in Figure 3.I.3 (b-d) and show common spherical shapes which are in a 
good agreement with previously published studies.
91, 92, 93
 However, it is obvious that there is a 
wide range of size distribution from small to large particles which decreases the uniformity of 
the NPs sizes.   
As a result, further solution filtration was carried out by using a Buchner funnel in order to 
obtain particles that are spherical but smaller in size and more uniform as mentioned earlier in 
section 2.2.3 and the results are presented in Figure 3.I.3 (e-g).
 
From the SEM images, one can see the appearance of similar shapes with no noticeable effect of 
the homogenization time on the shape of the prepared particles. Also, the solution settling step 
and the solution filtration by using a biological filter does not affect the shape of the particles, 
but rather affect the particle sizes and the PDI of the prepared particles. 
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Figure 3.I.3 (e-g) showed that filtration by using Buchner funnel did not affect the shape of the 
NPs by its vacuum pressure. In addition, high magnification powers were used because the 
particles are much smaller than PLGA-GO-NS-01 as a result of filtration by using the Buchner 
funnel which separated the small particles from the big ones. Moreover, the PLGA-GO-NF-01 
and NF-06 particles appear to be more uniform than those of PLGA-GO-NS-01 and this supports 
the results obtained from PCS and ensures that filtration by using Buchner funnel results in 
particles that are smaller in size and PDI and narrower in particles size distribution than those 
that were not filtered by using Buchner funnel.  
3.I.1.3 Structural evaluation of the PLGA-GO-NPs by FT-IR characterization  
The FT-IR spectra of GO alone, PLGA alone, the conjugated PLGA-GO-NS-01, the conjugated 
PLGA-GO-NF-01 and NF-06 are presented in Figure 3.I.4 (a-d). The FT-IR spectrum of PLGA-
GO-NF-01 was found to be the same as that of PLGA-GO-NF-06 as they were obtained from the 
same solution. 
 
Figure 3.I.4.  The FT-IR spectra of  (a) GO, (b) PLGA , (c) PLGA-GO-NS-01 and (d) PLGA-
GO-NF-01, NF-06 
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As illustrated in Figure 3.I.4, the FT-IR spectrum of PLGA showed spectral bands at  3500 cm
-1
 
(which could be attributed to OH stretching vibrations),  1750 cm
-1
 (that could be corresponding 
to C=O group), 1450 cm
-1
 & 1360 cm
-1
 (both could be corresponding to C-H bending), 1130 cm
-
1
 & 1090 cm
-1
 (both could be attributed to C-O stretching) and 750 cm
-1
 (that could be 
corresponding to C-H bending). These spectral bands were found to be in a good agreement with 
previously published reports. 
94 
On the other hand, the FT-IR spectrum of GO showed spectral bands at 3080 cm
-1
 
(corresponding to asymmetric stretching vibration of =CH2), 3008 cm
-1
 (attributed to C-H 
stretching), 2977 cm
-1
 (corresponding to symmetric stretching vibration of =CH2), 2904 cm 
-1
 
(corresponding to -CH2 stretching), very intense peak at 1634 cm
-1
 (attributed to C=C allyl 
group), double peak at 1423-1398 cm
-1
 may be assigned to the stretching -CH2- group, CH2=CH- 
stretching is shifted to 1216 cm 
-1
, very intense peak at 918 cm
-1
 (corresponding to C-S-C 
stretching vibration), 800-700 cm
-1
 (assigned to S-C group) and 500-400 cm
-1
 (assigned to S-S 
group). These spectral bands were found to be in a good agreement with previously published 
reports. 
79 
FT-IR spectrum of the PLGA-GO-NS-01 mixture showed an approximate superimposition of the 
individual peaks of both PLGA and GO, however, the FT-IR spectrum of PLGA-GO mixture 
shows no features similar to pure GO except for the double peak observed at 1423-1398 cm
-1
 
which is most probably assigned to the stretching -CH2- group which is common between the 
GO and the PLGA-GO-NS but absent in PLGA. Thus, this could actually be an indication of the 
incorporation of GO within PLGA NPs, Surprisingly, the spectral bands located at 3080, 3008, 
2977, 2904, 1634, 1423, 1216 and 918 cm
-1
 of GO had totally disappeared, while the GO bands 
were almost completely hindered by the very intense and broad PLGA bands and most probably 
Intra-molecular Hydrogen bonds between GO and PLGA might be formed. 
79
 
The FT-IR spectrum of PLGA-GO-NF-01 is found to be the same as that of PLGA-GO-NF-06 
with the same interpretation mentioned above (both spectra are superimposed on each other 
appearing as one spectrum).  
It is noticeable that the intensities of PLGA-GO-NF-01 and NF-06 peaks are much lower than 
those of PLGA-GO-NS-01 (Figure 3.I.5). This is reasonable because filtration by using Buchner 
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funnel was carried out and the filtered out particles are smaller, less intense and their peaks are 
highly separated.  
 
Figure 3.I.5. The difference in intensities between PLGA-GO-NS-01, NF-01 and NF-06 spectra. 
Moreover, it has been reported that PLGA has high affinity for carrying different types of guest 
molecules in its structure. PLGA is an aliphatic polyester, and has been reported to have good 
mechanical strength to carry a variety of guest molecules such as drugs, micro-molecules, 
vaccines, peptides, proteins and others. In addition, PLGA is characterized by acting as a 
reservoir in which drug molecules can be loaded through physical, chemical or electrostatic 
interactions according to their physicochemical properties.
33 
3.I.1.4. Determination of GO % in the PLGA-GO NPs  
In order to calculate the GO % in the PLGA-GO-NPs, the calibration curve (Figure 3.I.6) for 
standard GO was first constructed as mentioned earlier in chapter 2 section 2.3.6. The calibration 
curve was used in the calculation of the actual loaded % of GO in the PLGA-GO-NS-01, PLGA-
GO-NF-01 and NF-06 and then the GO % was calculated using equation 3.1 and the results are 
presented in Table 3.I.2. 
% GO content = (Actual loading/Theoretical loading) × 100……..equation 3.1 65 
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Figure 3.I.6. Calibration curve for standard GO. 
As can be seen in Table 3.I.2, the GO % slightly increased with increasing the homogenization 
time from 5 to 10 to 15 min, and this might be attributed to the longer homogenization time 
allowing the GO to be effectively incorporated within the PLGA NPs. Moreover, this might be 
because the longer homogenization time increased the particle sizes and the large NPs are able to 
carry more % of GO than small ones.  
On comparing the GO % in PLGA-GO-NS-01, PLGA-GO-NF-01 and NF-06, it was shown that 
the GO % is higher in NSs more than NFs. This could be because the high pressure applied by 
vacuum during filtration by using Buchner funnel causes the leakage of GO outside the PLGA 
NPs, but still the GO % in the PLGA-GO-NFs is reasonable and sufficient to carry out the 
antibacterial tests. 
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Table 3.I.2. The theoretical and actual GO % for the different formulations. 
 Theoretical content, % 
w/w 
Actual content, % 
w/w ±  s.d. 
GO % 
PLGA-GO-NS-01 
5min. 
homogenization 
5 2.54 ± 0.12 50.71 
PLGA-GO-NS-01 
10 min.  
homogenization 
5 2.61 ± 0.11 52.14 
PLGA-GO-NS 01  
15 min. 
 homogenization 
5 2.74 ± 0.04 54.85 
PLGA-GO-NF-01 and 06 
5 min. 
homogenization 
5 1.78 ± 0.03 35.64 
PLGA-GO-NF-01 and 06 
10 min. 
homogenization 
5 1.75 ± 0.01 35.06 
PLGA-GO-NF-01 and 06 
15 min. 
homogenization 
5 2.11 ± 0.04 42.18 
 
From the overall results presented in this section, it is worth mentioning that the (SE/SE) 
technique is effective in loading more than 50% of GO if NSs and more than 35% if NFs 
forming PLGA-GO-NPs and this is considered to be a noticeably high GO% noting that GO is 
volatile. Moreover, this preparation method was found to be beneficial to overcome the volatility 
of GO during use or storage as GO will be kept and protected within the PLGA NPs. Finally, this 
formulation is expected to improve the stability, solubility and bioavailability of GO. 
22 
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 3.I.2 Challenges during NPs preparation (poly-dispersed NPs) 
Many challenges have arisen during the preparation of PLGA-GO-NS-01, NF-01 and NF-06 that 
caused variations in the particles’ sizes and resulted in unstable NPs that had large nano-sizes 
variation and polydispersity index (PDI) which are summarized in chapter 2 section 2.2.4 (Figure 
2.4). 
In order to reach the stable NPs mentioned above, many steps were carried out resulting in the 
formation of poly-dispersed and unstable NPs and by following the scheme mentioned earlier in 
chapter 2 section 2.2.3 (Figure 2.2), gradual reduction in particle size has occurred in each step 
until reaching the smallest and stable particle nano-size. All the preparation parameters (such as 
the concentration of PLGA, concentration of GO, amounts of stabilizer and homogenization 
speed) were kept constant to identify the effect of the homogenization time (5, 10 and 15 min.) 
on the physicochemical properties of the PLGA-GO NPs. In addition, the effect of other factors 
such as (i) the effect of solution settling, (ii) the use of Buchner funnel in solution filtration, (iii) 
the use of biological filters in solution filtration and (iv) the effect of mechanically shaking the 
solutions by using vortex stirring on the PLGA-GO NPs preparation were carefully examined. 
  3.I.2.1 Particle size, PDI and Zeta potential of the different poly-dispersed PLGA-GO-NPs 
The particle sizes, PDI and zeta potential of the different poly-dispersed PLGA-GO NPs are 
summarized in Table 3.I.3. The particle sizes and zeta-potential of bulk GO and PLGA were 
recorded in order to evaluate the impact of the SE/SE technique on the PLGA and GO particles. 
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Table 3.I.3. The particle size ranges, PDI and zeta-potential of, GO, PLGA, PLGA-GO poly-
dispersed NPs. 
Loaded 
polymer 
Homogenization   
time (min.) 
Particle size 
range (nm) 
Poly-dispersity 
Index ± s.d 
Zeta-potential 
mV ± s.d 
GO (bulk) - 3508-3700 0.44 ± 0.17 -0.04 ± 0.01 
PLGA (bulk) - 2900-2945 0.48 ± 0.03 -0.23 ± 0.02 
PLGA-GO-NS-
02 
5  295-309 0.19 ± 0.04  
 
 
 
       -31.64 
± 
1.09 
10  329-378 0.17 ± 0.10 
15  337-367 0.32 ± 0.17 
PLGA-GO-NS-
03 
5 456-498 0.18 ± 0.11 
10  538-618 0.79 ± 0.30 
15  705-801 0.35 ± 0.10 
PLGA-GO-NS-
04 
5  243-359 0.34 ± 0.09 
10  415-560 0.53 ± 0.09 
15  390-909 0.66 ± 0.25 
PLGA-GO-
NF-02 
5  203-236 0.05 ± 0.03  
 
 
 
 
 
       -34.29 
           ± 
4.19 
 
10  230-263 0.08 ± 0.06 
15  247-285 0.16 ± 0.09 
PLGA-GO-
NF-03 
5  221-266 0.13 ± 0.08 
10  264-308 0.25 ± 0.07 
15  248-334 0.23 ± 0.09 
PLGA-GO-
NF-04 
5  203-239 0.19 ± 0.09 
10  180-251 0.20 ± 0.10 
15  188-368 0.32 ± 0.17 
PLGA-GO-
NF-05 
5  202-215 0.08 ± 0.06 
10  223-239 0.09 ± 0.06 
15  219-239 0.08 ± 0.06 
 
 
The particle size distribution histograms for PLGA-GO-NS-02, 03 and 04 are presented in 
Figures 3.I.7 (a-i) 
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 Figure 3.I.7. The particle size distribution for PLGA-GO-NS-02 (a, b, c), NS-03 (d, e, f) and 
NS-04 (g, h, i) prepared at homogenization time intervals of 5, 10 and 15 min.  
Figure 3.I.7 shows that the particle size distributions for the nano-suspension PLGA-GO-NS-02 
prepared at 5 min. homogenization time (a) ranges from 295 nm to 309 nm, at 10 min. 
homogenization time (b) ranges from 329 nm to 378 nm and that prepared at 15 min. 
homogenization time (c) ranges from 337 nm to 367 nm. 
Figure 3.I.7 shows that the particle size distributions for the nano-suspension PLGA-GO-NS-03 
prepared at 5 min. homogenization time (d) ranges from 456 nm to 498 nm, at 10 min. 
homogenization time (e) ranges from 538 nm to 618 nm and that prepared at 15 min. 
homogenization time (f) ranges from 705 nm to 801 nm. 
Figure 3.I.7 shows that the particle size distributions for the nano-suspension PLGA-GO-NS-04 
prepared at 5 min. homogenization time (g) ranges from 243 nm to 359 nm, at 10 min. 
homogenization time (h) ranges from 415 nm to 560 nm and that prepared at 15 min. 
homogenization time (i) ranges from 390 nm to 909 nm.   
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The particle size distribution histograms for PLGA-GO-NF-02, 03, 04 and 05 are presented in 
Figures 3.I.8 (a-l) 
 
 Figure 3.I.8. The particle size distribution for PLGA-GO-NF-02 (a, b, c), NF-03 (d, e, f), NF-04 
(g, h, i) and NF-05 (j, k, l) prepared at homogenization time intervals of 5, 10 and 15 min.  
Figure 3.I.8 shows that the particle size distributions for the nano-filtrate solution PLGA-GO-
NF-02 prepared at 5 min. homogenization time (a) ranges from 203 nm to 236 nm, at 10 min. 
homogenization time (b) ranges from 230 nm to 263 nm and that prepared at 15 min. 
homogenization time (c) ranges from 247 nm to 285 nm. 
Figure 3.I.8 shows that the particle size distributions for the nano-filtrate solution PLGA-GO-
NF-03 prepared at 5 min. homogenization time (d) ranges from 221 nm to 266 nm, at 10 min. 
homogenization time (e) ranges from 264 nm to 308 nm and that prepared at 15 min. 
homogenization time (f) ranges from 248 nm to 334 nm. 
Figure 3.I.8 shows that the particle size distributions for the nano-filtrate solution PLGA-GO-
NF-04 prepared at 5 min. homogenization time (g) ranges from 203 nm to 239 nm, at 10 min. 
homogenization time (h) ranges from 180 nm to 251 nm and that prepared at 15 min. 
homogenization time (i) ranges from 188 nm to 368 nm. 
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Figure 3.I.8 shows that the particle size distributions for the nano-filtrate solution PLGA-GO-
NF-05 prepared at 5 min. homogenization time (j) ranges from 202 nm to 215 nm, at 10 min. 
homogenization time (k) ranges from 223 nm to 239 nm and that prepared at 15 min. 
homogenization time (l) ranges from 219 nm to 239 nm. 
According to Table 3.I.3 and Figures 3.I.7 and 3.I.8, the particle sizes and PDI increase upon 
increasing the homogenization time from 5 to 10 to 15 min, (at the same homogenization speed 
of 11,000 rpm) showing that increasing homogenization time can increase the average particle 
size and PDI for the same reasons mentioned earlier in section 3.I.1. Moreover, the results 
revealed that settling of the solution, filtration through a biological filter and/or filtration by 
using Buchner funnel have a great influence on the particle sizes, size distribution and PDI of the 
NPs. These parameters lead to a pronounced decrease in average particle size, size distribution 
and PDI. One can conclude that Buchner filtration, followed by settling of the filtrate then 
filtration through a biological filter is necessary to obtain stable NPs of small and uniform sizes. 
It is worth mentioning that SEM images, FT-IR spectra and the GO% were the same as the 
formulations mentioned earlier in section 3.I.1. However, the zeta-potential of these formulations 
are slightly lower than that of PLGA-GO-NS-01, NF-01 and NF-06. This might be due to the 
aggregation of the particles due to their large sizes. 
3.I.2.2 Morphological examination of PLGA-GO-NPs by SEM 
The morphology of PLGA-GO-NS-02, 03 and 04 prepared at homogenization time intervals of 
5, 10 and 15 min. are same to that of PLGA-GO-NS-01 and the morphology of PLGA-GO-NF-
02, 03, 04 and 05 prepared at homogenization time intervals of 5, 10 and 15 min. are same to that 
of PLGA-GO-NF-01 and NF-06. This is because they are all obtained from the same suspension. 
It was shown earlier that the solution settling and Buchner filtration did not affect the shape of 
the NPs, but affect the particle sizes distribution. As a consequence, the NPs prepared at 
homogenization time of 5 min. were chosen and their SEM images are presented in Figure 3.I.9  
 
65 
 
 
Figure 3.I.9. SEM images for PLGA-GO (a) NS-02, (b) NS-03, (c) NS-04, (d) NF-02, (e) NF-
03, (f) NF-04 and (g) NF-05 prepared at homogenization time of 5 min.  
3.I.2.3 Structural evaluation of the PLGA-GO-NPs by FT-IR characterization 
The spectra of PLGA-GO-NS 02, 03 and 04 are same to each other, superimposed on each other 
and appear as one spectrum and their spectrum is the same as that of PLGA-GO-NS-01. In 
addition, the FT-IR spectra of PLGA-GO-NF 02, 03, 04 and 05 are same to each other, 
superimposed on each other and appear as one spectrum and their spectrum is the same as that of 
PLGA-GO-NF-01. The spectra of PLGA-GO-NS-02, 03, 04 and NF-02, 03, 04 and 05 are 
presented in Figure 3.I.10 and described earlier in section 3.I.1.3. 
 
Figure 3.I.10. The FT-IR spectra of PLGA-GO-NS-02, 03, 04 and NF-02, 03, 04 and 05. 
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3.I.2.4 Determination of GO% in the PLGA-GO-NPs 
The GO% in PLGA-GO-NS-02, 03 and 04, PLGA-GO-NF-02, 03, 04 and 05 is the same as that 
of PLGA-GO-NS-01 and PLGA-GO-NF-01 and 06 (Table 3.I.4). 
Table 3.I.4. The theoretical and actual GO % for the different formulations. 
 Theoretical content, % 
w/w 
Actual content, % 
w/w ± s.d. 
 
GO % 
PLGA-GO-NS-02, 03 
&04 
(5min.homogenization) 
5 2.54 ± 0.12 50.71 
PLGA-GO-NS-02, 03 & 
04 
(10 min. homogenization) 
5 2.61 ± 0.11 52.14 
PLGA-GO-NS 02, 03 & 
04 
(15 min. homogenization) 
5 2.74 ± 0.04 54.85 
PLGA-GO-NF-02, 03, 04 
& 05 
(5min.homogenization) 
5 1.78 ± 0.03 35.64 
PLGA-GO- NF-02, 03, 04 
& 05 
(10 min. homogenization) 
5 1.75 ± 0.01 35.06 
PLGA-GO- NF-02, 03, 04 
& 05 
(15 min. homogenization) 
5 2.11 ± 0.04 42.18 
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3.I.2.5 SEM: longer exposure time and structural defects 
It was observed that longer exposure time to the SEM caused structural defects that are presented 
in Figure 3.I.11 (a-c). 
 
Figure 3.I.11. The structural defects occurred to the NPs during SEM measurement. 
According to Figure 3.I.11 , it has been observed occasionally that long time exposure to electron 
beams of SEM (longer than 1 min.) can cause heating of the mounted samples which causes 
some merging/fusion of NPs together to form clusters. This is most probably because the heat 
generated by the electron beam of the SEM could melt and soften the PLGA walls. This could 
possibly explain why the tentative sizes obtained from the SEM images were found to be much 
larger than those obtained by the PCS. 
22 
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3.II Synthesis and characterization of PLGA-PEG-GO-NPs 
 3.II.1 Mono-dispersed PLGA-PEG-GO-NPs  
Another polymer (PEG) was added to PLGA and the same set of experiments mentioned in 
section 3.I were applied. 
The different mono-dispersed PLGA-PEG-GO NPs were prepared as mentioned earlier in 
chapter 2 section 2.2.3 and illustrated in Figure 2.2, where PLGA-PEG-GO-NS-01 is the nano-
suspension obtained after solution settling and filtration through a biological filter, PLGA-PEG-
GO-NF-01 is the nano-suspension obtained by filtration through a Buchner funnel, Thereafter 
left to settle for 24hr and then, filtered again through a biological filter, and PLGA-PEG-GO-NF-
06 which was obtained by mechanical shaking by using vortex stirring of PLGA-PEG-GO-NF-
01. 
3.II.1.1 Particle size, PDI and Zeta potential of the different mono-dispersed PLGA-PEG-
GO-NPs 
The particle sizes range, PDI and zeta potential of the different PLGA-PEG-GO-NPs are 
summarized in Table 3.II.1 The particle sizes and zeta-potential of bulk GO, PLGA and PEG 
were recorded in order to evaluate the impact of the SE/SE technique on the size of PLGA and 
GO particles. 
From Table 3.II.1, one can notice that the size of PLGA-PEG-GO particles have decreased by 
more than 120 folds from the original size of the PLGA, PEG and GO bulk samples. 
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Table 3.II.1. The particle size ranges, PDI and zeta-potential of GO, PLGA, PEG, PLGA-PEG-
GO-NS-01, PLGA-PEG-GO-NF-01 and PLGA-PEG-GO-NF-06. 
Loaded 
polymer 
Homogenization 
time 
(min.) 
Particle size 
range (nm) 
Poly-
dispersity 
Index ± s.d 
Zeta-potential mV ± 
s.d 
GO (bulk) - 3508-3700 0.44 ± 
0.17 
-0.04 ± 
0.01 
PLGA (bulk) - 2900-2945 0.48 ± 
0.03 
-0.23 ± 
0.02 
PEG (bulk) - 1770-1975 1±  
0 
0.56± 
0.03 
PLGA+PEG 
(bulk) 
- 4034-5184 0.79 ± 
0.3 
-0.12± 
0.07 
PLGA-PEG-
GO-NS-01 
5  229-240 0.16 ± 
        0.07 
 
 
              -28.26 
± 
3.74 
 
10  232-244 0.15 ± 
0.02 
15  264-293 0.33 ± 
0.18 
PLGA-PEG-
GO-NF-01 
5  170-212 0.08 ± 
0.05 
 
              -30.94  
±  
2.53 
 
 
 
 
 
 
 
 
10  190-225 0.13 ± 
0.06 
15  205-237 0.15 ± 
0.07 
PLGA-PEG-
GO-NF-06 
5  184-189 0.11 ± 
0.09 
10  181-219 0.07 ± 
0.04 
15  199-227 0.14 ± 
0.07 
 
The particle size distribution histograms for PLGA-PEG-GO-NS-01, PLGA-PEG-GO-NF-01 
and PLGA-PEG-GO-NF-06 obtained at different homogenization times (5, 10 and 15 min.) are 
illustrated in Figure 3.II.1 (a-i). 
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Figure 3.II.1. The particle size distribution for PLGA-PEG-GO-NS-01 (a, b, c), NF-01 (d, e, f), 
NF-06 (g, h, i) prepared at homogenization time intervals of 5, 10 and 15 min. 
Figure 3.II.1 shows that the particle size distributions for the nano-suspension PLGA-PEG-GO- 
NS-01 prepared at 5 min. homogenization time (a) ranges from 229 nm to 240 nm, at 10 min. 
homogenization time (b) ranges from 232 nm to 244 nm and that prepared at 15 min. 
homogenization time (c) ranges from 264 nm to 293 nm. 
Figure 3.II.1 shows that the particle size distributions for the nano-filtrate solution PLGA-PEG-
GO-NF-01 prepared at 5 min. homogenization time (d) ranges from 170 nm to 212 nm, at 10 
min. homogenization time (e) ranges from 190 nm to 225 nm and that prepared at 15 min. 
homogenization time (f) ranges from 205 nm to 237 nm. 
Figure 3.II.1 shows that the particle size distributions for the nano-filtrate solution PLGA-PEG-
GO-NF-06 prepared at 5 min. homogenization time (g) ranges from 184 nm to 189 nm, at 10 
min. homogenization time (h) ranges from 181 nm to 219 nm and that prepared at 15 min. 
homogenization time (i) ranges from199nm to 227 nm. 
According to Table 3.II.1 and Figure 3.II.1 (a-i), and as mentioned earlier in section 3.I.1.1, the 
particle sizes and the PDI increased upon increasing the homogenization time from 5 to 10 to 15 
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min, (at the same homogenization speed of 11,000 rpm). This could possibly be because as the 
homogenization time increases, the high shear stress of the homogenizer will result in the 
aggregation of the colloidal particles into larger ones, and thus increasing the PDI. In addition, 
PLGA might have melten by the high mechanical energy, due to the high homogenization speed, 
leading to the instability of the particles.
85
 The results revealed that the 5 min. homogenization 
time was more efficient to form NPs with smaller particle sizes and narrower PDI and at the 
same time, it is not too long to cause the aggregation of the colloidal particles.  
Moreover, as shown in Table 3.II.1 the particle sizes and the PDI decreased (in comparison to the 
other PLGA-PEG-GO-NSs that will be mentioned in section 3.II.2.1), when the suspension was 
left to settle followed by filtration through a biological filter. As a result, PLGA-PEG-GO-NS-01 
prepared at homogenization time 5 min. was found to have smaller particle sizes and lower PDI 
in comparison to the NSs prepared at homogenization times of 10 and 15 min. where PLGA-
PEG-GO-NS-01 was found to have much smaller particle sizes and PDI than PLGA-PEG-GO-
NS-02, PLGA-PEG-GO-NS-03 and PLGA-PEG-GO-NS-04 that will be mentioned in the next 
section (section 3.II.2.1).   
In addition, it is noticeable that PLGA-PEG-GO-NF-01 has much smaller particle sizes in 
comparison to PLGA-PEG-GO-NS-01 formulation (Figure 3.II.2). This is because filtration by 
using Buchner funnel removed the large particles and kept the small mono-dispersed ones 
resulting in increasing the stability and decreasing the PDI and size distribution. In addition, the 
effect of mechanical shaking the solution by using vortex stirring was studied on PLGA-PEG-
GO-NF-01 resulting in PLGA-PEG-GO-NF-06. When the size of PLGA-PEG-GO-NF-06 was 
compared to that of PLGA-PEG-GO-NF-01, it was found that vortex stirring decreased the 
particle size ranges and PDI of PLGA-PEG-GO-NF-06 formulations prepared at homogenization 
times of 5, 10 and 15 min. This might be because vortex stirring separated any aggregated 
particles and as a result, it is recommended that PLGA-PEG-GO-NFs formulations should be 
vigorously shaken before use. 
Furthermore, it was found that the particle sizes of PLGA-PEG-GO-NS-01, PLGA-PEG-GO-
NF-01 and PLGA-PEG-GO-NF-06 are much lower than that of PLGA-GO-NS-01, PLGA-GO-
NF-01 and PLGA-GO-NS-06 and the PDIs are much narrower. This might be because as has 
previously been reported, PEG acts as a surfactant that produces uniform finer emulsion droplets 
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through lowering the interfacial tension of the emulsion during the NPs preparation. 
(95-98) 
As a 
result, PLGA-PEG-GO formulations are much stable in suspension than PLGA-GO formulations 
because they have lower sizes and narrower PDIs.
88
   On the other hand, it was also reported that 
increasing the M.wt or content of PEG, increases the polymeric aggregation and the water uptake 
producing a more compact steric arrangement giving larger nanoparticles with wider PDI. As a 
result, 100 mg of PEG with M.wt 6000 was employed in this study. 
60,
 
96, 99, 100
 
The average zeta-potential for PLGA-PEG-GO-NS-01was found to be -28.26 ± 3.74 indicating 
the surface charges of the PLGA/GO composite NPs which limits their aggregation. Therefore, 
PLGA-PEG-GO-NS achieves the highest stability and the minimum particles aggregation. This 
is attributed to the fact that as the zeta potential increases either by negative or positive, and this, 
in turn, indicates that the stability of the particles suspension increases and the particles 
aggregation decreases as the charged particles can repel one another. 
86, 87
Also, the average zeta-
potential for PLGA-PEG-GO-NF-01 and PLGA-PEG-GO-NF-06 was found to be -30.94 ± 2.53 
which is higher in negative charge than that of PLGA-PEG-GO-NS-01 (-28.26 ± 3.74) and this is 
because the filtration through a Buchner funnel decreased the agglomeration of the particles 
which caused the negative charge of the uncapped end carboxylic groups of PLGA to be more 
exposed on the surface of the particles.  
Moreover, it is shown that the zeta potential of PLGA-PEG-GO- NS-01 (-28.26 ± 3.74) is lower 
in negative charge than that of PLGA-GO-NS-01 (-33.69 ± 3.35) and the zeta potential of 
PLGA-PEG-GO NFs (-30.94 ± 2.53) is lower in negative charge than that of PLGA-GO-NFs      
(-35.37±4.62). This is because as has previously been reported, coating of the NPs with 
surfactants such as PEG (amiphiphilic polymers that possess hydrophilic characters) reduce the 
zeta potential because the coating layers can mask the surface charge of the uncapped end 
carboxylic groups of the polyester. This proves that part of the surfactant molecules are located 
on the surface of the NPs producing lower zeta potential values. 
89, 101
 Zeta potential of the 
particles is also affected by the amount the hydrophilic polymers used where by increasing the 
content of the hydrophilic polymers, more reduction of the zeta potential will occur due to 
enhancement of the shielding effect of the hydrophilic polymers at the nanoparticle surface.
87
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Figure 3.II.2. A comparison between the average particle sizes (nm) of PLGA-PEG-GO-NS-01, 
PLGA-PEG-GO-NF-01 and PLGA-PEG-GO-NF-06 recorded at different homogenization time 
intervals (5, 10 and 15 min.).  
3.II.1.2  Morphological examination of  PLGA-PEG-GO-NPs by SEM 
SEM was used to determine the shape and surface morphology of the prepared PLGA-PEG-GO 
composite NPs. SEM images of blank PLGA particles is illustrated in section 3.I.1.2, SEM 
images of blank PEG particles, PLGA-PEG-GO-NS-01, NF-01 and NF-06 prepared at 5, 10 and 
15 min. homogenization time intervals are presented in Figure 3.II.3 (a-g) where the SEM 
images of NF-01 and NF-06 are the same because they were obtained from the same solution.  
 
Figure 3.II.3 SEM images for (a) blank bulk PLGA particles, PLGA-PEG-GO-NS-01 (b, c, d), 
NF-01 and NF-06 (e, f, g) prepared at homogenization time intervals of 5, 10 and 15 min. 
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The SEM images of PLGA-PEG-GO-NS-01 prepared at homogenization time intervals of 5, 10 
and 15 min. are presented in Figures 3.II.3 (b-d) show common spherical shapes which are in a 
good agreement with previously published studies. 
91, 92, 93, 98
 However, it is obvious that there is 
a wide range of size distribution from small to large particles which decreases the uniformity of 
the NPs sizes. 
As a result, further solution filtration was carried out by using a Buchner funnel in order to 
obtain particles that are spherical but smaller in size and more uniform as mentioned in section 
2.2.3 and the results are presented in Figure 3.II.3 (e-g). 
From the SEM images, one can see the appearance of similar shapes with no noticeable effect of 
the homogenization time on the shape of the prepared particles. Also, the solution settling step 
and the solution filtration by using a biological filter does not affect the shape of the particles, 
but rather affect the particle sizes and the PDI of the prepared particles. Furthermore, it is 
obvious that the addition of PEG does not affect the morphology of the prepared NPs, where the 
morphology of PLGA-PEG-GO-NS-01 is similar to that of PLGA-GO-NS-01. 
Figure 3.II.3 (e-g) showed that filtration by using Buchner funnel did not affect the shape of the 
NPs by its vacuum pressure. In addition, high magnification powers were used because the 
particles are much smaller than PLGA-PEG-GO-NS-01 as a result of filtration by using the 
Buchner funnel which separated the small particles from the big ones. Moreover, the PLGA-
PEG-GO-NFs particles appear to be more uniform than those of PLGA-PEG-GO-NSs and this 
supports the results obtained from PCS and ensures that filtration by using Buchner funnel 
results in particles that are smaller in size and PDI and narrower in particles size distribution than 
those that were not filtered by using Buchner funnel.  
3.II.1.3 Structural evaluation of the PLGA-PEG-GO-NPs by FT-IR characterization 
The FT-IR spectra of GO and PLGA are presented in section 3.I.1.3. PEG alone, the conjugated 
PLGA-PEG-GO-NS-01, NF-01 and NF-06 are presented in Figure 3.II.4. The FT-IR spectrum of 
PLGA-PEG-GO-NF-01 was found to be the same as that of PLGA-PEG-GO-NF-06 as they were 
obtained from the same solution. 
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Figure 3.II.4. The FT-IR spectra of (a) PEG, (b) PLGA-PEG-GO-NS-01, (c) PLGA-PEG-GO-
NF-01 and NF-06. 
The FT-IR spectra of PLGA and GO are interpreted earlier in section 3.I.1.3. The FT-IR 
spectrum of PEG Figure3.II.4 (a) showed spectral bands at 3424 cm
-1
 ( which could be attributed 
to OH stretching vibrations), 2885 cm
-1
 (that could be corresponding to C-H stretching of CH2 
group), 1115cm
-1
, 1130 cm
-1
 & 1090 cm
-1
  (that could be corresponding to C-O-C stretching 
vibration of the repeated –OCH2CH2 units of PEG backbone), 843 cm
-1
 and 750 cm
-1
 (that could 
be corresponding to C-H bending). These spectral bands were found to be in a good agreement 
with previously published reports. 
98, 102
 
FT-IR spectrum of the PLGA-PEG-GO-NS-01 mixture which is presented in Figure 3.II.4 (b) 
showed an approximate superimposition of the individual peaks of PLGA, PEG and GO, 
however, the FT-IR spectrum of PLGA-PEG-GO mixture shows no features similar to pure GO 
except for the double peak observed at 1423-1398 cm 
-1
 which is most probably assigned to the 
stretching -CH2- group which is common between the GO and the PLGA-PEG-GO-NS but 
absent in PLGA and PEG. Moreover, the peak observed at 1115 cm
-1
 is common between the 
PEG and the PLGA-PEG-GO-NS indicating that PEG has been successfully coated on the NPs. 
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Thus, this could actually be an indication of the incorporation of GO within PLGA-PEG NPs, 
Surprisingly, the spectral bands located at 3080, 3008, 2977, 2904, 1634, 1423, 1216 and 918  
cm 
-1
 of GO had totally disappeared, while the GO bands were almost completely hindered by 
the very intense and broad PLGA and PEG bands and most probably Intra-molecular Hydrogen 
bonds between GO, PLGA and PEG might be formed.  
79, 98, 103
 
The FTIR spectrum of PLGA-GO-NF-01 which is presented in Figure 3.II.4 (c) is found to be 
the same as that of PLGA-GO-NF-06 with the same interpretation mentioned above (both 
spectra are superimposed on each other appearing to be one spectrum). 
It is noticeable that the intensities of both PLGA-PEG-GO-NF-01 and NF-06 peaks are much 
lower than those of PLGA-PEG-GO-NSs (Figure 3.II.5). This is reasonable because filtration by 
using Buchner funnel was carried out and filtered out particles are smaller, less intense and their 
peaks are highly separated. 
 
Figure 3.II.5. The difference in intensities between PLGA-PEG-GO-NS-01 and PLGA-PEG-
GO-NF-01 and NF-06 spectra. 
PEG can act as surfactant by accumulating at the inner interface of the NPs which consists of the 
polymer mixture of PLGA and PEG leading to spreading GO throughout the inner phase.
 103 
3.II.1.4 Determination of GO % in the PLGA-PEG-GO NPs
 
According to the calibration curve and equation 3.1 mentioned earlier in section 3.I.1.4, the GO 
% in PLGA-PEG-GO-NS-01, PLGA-PEG-GO-NF-01 and NF-06 prepared at homogenization 
times of 5, 10 & 15 min. is calculated and the results are presented in Table 3.II.2. 
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Table 3.II.2. The theoretical and actual GO % for the different formulations. 
 Theoretical content, 
% w/w 
Actual content, % 
w/w ± s.d. 
 
GO % 
PLGA-PEG-GO-
NS- 01 
5 min. 
homogenization 
 
 
5 
 
2.58  
± 
0.07 
 
 
51.6 
 
PLGA-PEG-GO-
NS- 01 
10 min. 
homogenization 
 
 
5 
 
2.79  
± 
0.04 
 
 
55.8 
PLGA-PEG-GO-
NS- 01 
15 min. 
homogenization 
 
 
5 
 
3.11  
± 
0.03 
 
 
62.6 
PLGA-PEG-GO-
NF- 01 and 06 
5 min. 
homogenization 
 
 
5 
 
1.89 
± 
0.09 
 
 
37.8 
PLGA-PEG-GO-
NF- 01 and 06 
10 min. 
homogenization 
 
 
5 
 
1.93 
± 
0.05 
 
 
38.6 
PLGA-PEG-GO-
NF- 01 and 06 
15 min. 
homogenization 
 
 
5 
 
2.25 
± 
0.01 
 
 
45 
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As can be seen in Table 3.II.2, the GO % slightly increased with increasing the homogenization 
time from 5 to 10 to 15 min, and this might be attributed to the longer homogenization time 
allowing the GO to be effectively incorporated within the PLGA-PEG NPs and also, the increase 
in particle sizes increase the GO% content as mentioned earlier. 
On comparing the GO % in PLGA-PEG-GO-NSs and PLGA-PEG-GO-NFs, it was shown that 
the GO % is higher in NSs more than NFs. This could be because of the high pressure applied by 
vacuum during filtration by using Buchner funnel causes the leakage of GO outside the PLGA 
NPs, but still the GO % in the PLGA-PEG-GO-NFs is reasonable and sufficient to exert the 
antibacterial action. 
Furthermore, it is noticeable that the GO % is higher in PLGA-PEG-GO formulations than in 
PLGA-GO formulations this is because PEG coats the NPs forming a barrier that surrounds and 
protects GO reservoir resulting in protecting GO during emulsification and keeps its stability.
98
  
It is worth mentioning that the (SE/SE) technique is effective in loading more than 50% of GO 
forming PLGA-PEG-GO-NC and this is considered to be a noticeably high GO% noting that GO 
is volatile. Moreover, this preparation method was found to be beneficial to overcome the 
volatility of GO during use or storage as GO will be kept and protected within the PLGA-PEG 
NPs. Finally, this formulation is expected to improve the stability, solubility and bioavailability 
of GO.
22
  
From the overall results, it is obvious that this newly formed amphiphilic PLGA-PEG-GO- NS-
01, NF-01 and NF-06 prepared at homogenization time of 5 min. has better physicochemical 
properties than the other PLGA-PEG-GO and PLGA-GO formulations e.g. higher drug loading 
efficiencies, smaller sizes and narrower PDI(s). 
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3.II.2 Challenges during NPs preparation (poly-dispersed NPs) 
As mentioned earlier in section 3.I.2, many challenges have arisen during the preparation of 
PLGA-PEG-GO-NS-01, NF-01 and NF-06 that caused variations in the particles’ sizes and 
resulted in unstable NPs that had large nano-sizes variation and polydispersity index (PDI) which 
are summarized in chapter 2 section 2.2.4 (Figure 2.4). 
In order to reach the stable NPs mentioned above, many steps were carried out resulting in the 
formation of poly-dispersed and unstable NPs and by following the scheme mentioned earlier in 
chapter 2 section 2.2.3, gradual reduction in particle sizes has occurred in each step until 
reaching the smallest and stable particle nano-size. All the preparation parameters (such as the 
concentration of PLGA, concentration of PEG, concentration of GO, amounts of stabilizer and 
homogenization speed) were kept constant to identify the effect of the homogenization time (5, 
10 and 15 min.) on the physicochemical properties of the PLGA-PEG-GO NPs. In addition, the 
effect of other factors such as the effect of solution settling, the use of Buchner funnel in solution 
filtration, the use of biological filters in solution filtration and the effect of mechanically shaking 
the solutions by using vortex stirring on the PLGA-PEG-GO NPs preparation were carefully 
examined. 
3.II.2.1 Particle size, PDI and zeta- potential of the different poly-dispersed PLGA-PEG-
GO-NPs 
The particle size ranges, PDI and zeta potential of the different PLGA-GO poly-dispersed NPs 
are summarized in Table 3.II.3. 
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Table 3.II.3. The particle size ranges, PDI and zeta-potential of poly-dispersed PLGA-PEG-GO- 
NPs 
Loaded 
polymer 
Homogenization 
time (min.) 
Particle size 
range (nm) 
Poly-dispersity 
Index ± s.d 
Zeta-potential 
mV ± s.d 
GO (bulk) - 3508-3700 0.44 ± 0.17 -0.04 ± 0.01 
PLGA (bulk) - 2900-2945 0.48 ± 0.03 -0.23 ± 0.02 
PEG (bulk) - 1770-1975 1± 0 0.56 ± 0.03 
PLGA+PEG 
(bulk) 
- 4034-5184 0.79 ± 0.3 -0.12 ± 0.07 
PLGA-PEG-
GO-NS-02 
5  254-265 0.17 ± 0.03  
 
 
 
 
-26.29 
± 
3.19 
10  271-280 0.14 ± 0.04 
15  315-327 0.16 ± 0.10 
PLGA-PEG-
GO-NS-03 
5  425-477 0.54 ± 0.13 
10  653-755 0.62 ± 0.07 
15  743-817 0.65 ± 0.39 
PLGA-PEG-
GO-NS-04 
5  239-391 0.36 ± 0.09 
10  251-627 0.63 ± 0.17 
15  343-922 0.76 ± 0.21 
PLGA-PEG-
GO-NF-02 
5  204-219 0.12 ± 0.08  
 
 
 
 
-29.73 
± 
2.84 
10  207-254 0.10 ± 0.05 
15  237-271 0.13 ± 0.10 
PLGA-PEG-
GO-NF-03 
5  226-235 0.17 ± 0.11 
10  233-268 0.15 ± 0.10 
15  248-304 0.19 ± 0.06 
PLGA-PEG-
GO-NF-04 
5  205-229 0.16 ± 0.08 
10  204-233 0.15 ± 0.04 
15  217-244 0.20 ± 0.08 
PLGA-PEG-
GO-NF-05 
5  186-205 0.11 ± 0.08 
10  192-230 0.11 ± 0.07 
15  203-236 0.09 ± 0.05 
 
The particle size distribution histograms for PLGA-PEG-GO-NS-02, 03 and 04 are presented in 
Figure 3.II.6 (a-i). 
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Figure 3.II.6. The particle size distribution for PLGA-PEG-GO-NS-02 (a, b, c), NS-03 (d, e, f) 
and NS-04 (g, h, i) prepared at homogenization time intervals of 5, 10 and 15 min.  
Figure 3.II.6 shows that the particle size distribution for the nano-suspension PLGA-PEG-GO-
NS-02 prepared at 5 min. homogenization time (a) ranges from 254 nm to 265 nm, at 10 min. 
homogenization time (b) ranges from 271 nm to 280 nm and that prepared at 15 min. 
homogenization time (c) ranges from 315 nm to 327 nm. 
Figure 3.II.6 shows that the particle size distributions for the nano-suspension PLGA-PEG-GO-
NS-03 prepared at 5 min. homogenization time (d) ranges from 425 nm to 477 nm, at 10 min. 
homogenization time (e) ranges from 653 nm to 755 nm and that prepared at 15 min. 
homogenization time (f) ranges from 743 nm to 817 nm. 
Figure 3.II.6 shows that the particle size distributions for the nano-suspension PLGA-PEG-GO-
NS-04 prepared at 5 min. homogenization time (g) ranges from 239 nm to 391 nm, at 10 min. 
homogenization time (h) ranges from 251 nm to 627 nm and that prepared at 15 min. 
homogenization time (i) ranges from 343 nm to 922 nm.   
The particle size distribution histograms for PLGA-PEG-GO-NS-02, 03 and 04 are presented in 
Figure 3.II.7 (a-l). 
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Figure 3.II.7. The particle size distribution for PLGA-PEG-GO-NF-02 (a, b, c), NF-03 (d, e, f) 
NF-04 (g, h, i) and NF-05 (j, k, l) prepared at homogenization time intervals of 5, 10 and 15 min.  
Figure 3.II.7 shows that the particle size distributions for the nano-filtrate solution PLGA-PEG-
GO-NF-02 prepared at 5 min. homogenization time (a) ranges from 204 nm to 219 nm, at 10 
min. homogenization time (b) ranges from 207 nm to 254 nm and that prepared at 15 min. 
homogenization time (c) ranges from 237 nm to 271 nm. 
  Figure 3.II.7 shows that the particle size distributions for the nano-filtrate solution PLGA-PEG-
GO-NF-03 prepared at 5 min. homogenization time (d) ranges from 226 nm to 235 nm, at 10 
min. homogenization time (e) ranges from 233 nm to 268 nm and that prepared at 15 min. 
homogenization time (f) ranges from 248 nm to 304 nm. 
Figure 3.II.7 shows that the particle size distributions for the nano-filtrate solution PLGA-PEG-
GO-NF-04 prepared at 5 min. homogenization time (g) ranges from 205 nm to 229 nm, at 10 
min. homogenization time (h) ranges from 204 nm to 233 nm and that prepared at 15 min. 
homogenization time (i) ranges from 217 nm to 244 nm. 
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Figure 3.II.7 shows that the particle size distributions for the nano-filtrate solution PLGA-PEG-
GO-NF-05 prepared at 5 min. homogenization time (j) ranges from 186 nm to 205 nm, at 10 min. 
homogenization time (k) ranges from 192 nm to 230 nm and that prepared at 15 min. 
homogenization time (l) ranges from 203 nm to 236 nm. 
According to Table 3.II.3 and Figures 3.II.6 and 3.II.7, the average particle size and PDI increase 
upon increasing the homogenization time from 5 to 10 to 15 min, (at the same homogenization 
speed of 11,000 rpm) showing that increasing homogenization time can increase the average 
particle size and PDI for the same reasons mentioned earlier in section 3.II.1.1 Moreover, the 
results revealed that settling of the solution, filtration through a biological filter and/or filtration 
by using Buchner funnel have a great influence on the average particle sizes, size distribution 
and PDI of the NPs. These parameters lead to a pronounced decrease in average particle size, 
size distribution and PDI. One can conclude that Buchner filtration, followed by settling of the 
filtrate then filtration through a biological filter is necessary to obtain stable NPs of small and 
uniform sizes. 
It is worth mentioning that the SEM images, FT-IR spectra and the GO% were the same as the 
formulations mentioned earlier in section 3.II.1. However, the zeta-potential of these 
formulations are slightly lower than that of PLGA-PEG-GO-NS-01, NF-01 and NF-06. This 
might be due to the aggregation of the particles due to their larger sizes. 
3.II.2.2 Morphological examination of PLGA-PEG-GO-NPs by SEM 
The morphology of PLGA-GO-NS-02, 03 and 04 prepared at homogenization time intervals of 
5, 10 and 15 min. are same to that of PLGA-GO-NS-01 and the morphology of PLGA-GO-NF-
02, 03, 04 and 05 prepared at homogenization time intervals of 5, 10 and 15 min. are same to that 
of PLGA-GO-NF-01 and NF-06. This is because they are all obtained from the same suspension. 
It was shown earlier that the solution settling and Buchner filtration did not affect the shape of 
the NPs, but affect the particle sizes distribution. As a consequence, the NPs prepared at 
homogenization time of 5 min. were chosen and their SEM images are presented in Figure 3.II.8  
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Figure 3.II.8. SEM images for PLGA-PEG-GO (a) NS-02, (b) NS-03, (c) NS-04, (d) NF-02, (e) 
NF-03, (f) NF-04 and (g) NF-05 prepared at homogenization time of 5 min.  
3.II.2.3 Structural evaluation of the PLGA-PEG-GO-NPs by FT-IR characterization 
The spectra of PLGA-PEG-GO-NS 02, 03 and 04 are same to each other, superimposed on each 
other and appear as one spectrum and their spectrum is the same as that of PLGA-PEG-GO-NS-
01 In addition, the FT-IR spectra of PLGA-PEG-GO-NF 02, 03, 04 and 05 are same to each 
other, superimposed on each other and appear as one spectrum and their spectrum is the same as 
that of PLGA-PEG-GO-NF-01. The spectra of PLGA-PEG-GO-NS-02, 03, 04 and NF-02, 03, 04 
and 05 are presented in Figure 3.II.9. 
 
Figure 3.II.9. The FT-IR spectra of PLGA-PEG-GO-NS-02, 03, 04 and NF-02, 03, 04 and 05. 
86 
 
3.II.2.4 Determination of GO% in the PLGA-PEG-GO-NPs 
The GO% in PLGA-PEG-GO-NS-02, 03 and 04, PLGA-PEG-GO-NF-02, 03, 04 and 05 is the 
same as that of PLGA-PEG-GO-NS-01 and PLGA-PEG-GO-NF-01 and 06 (Table 3.II.4). 
Table 3.II.4. The theoretical and actual GO % for the different formulations. 
 Theoretical 
content, % w/w 
Actual content, 
% w/w ± s.d. 
 
GO % 
PLGA-PEG-GO-NS-02, 03 
and 04 
(5 min.homogenization) 
 
 
5 
 
2.58 ± 
0.07 
 
 
51.6 
 
PLGA-PEG-GO-NS- 02, 
03 and 04 
(10 min. homogenization) 
 
 
5 
 
2.79 ± 
0.04 
 
 
55.8 
PLGA-PEG-GO-NS- 02, 
03 and 04 
(15 min. homogenization 
 
 
5 
 
3.11 ± 
0.03 
 
 
62.6 
PLGA-PEG-GO-NF- 02, 
03, 04 and 05 
(5 min. homogenization) 
 
 
5 
 
1.89 ± 
0.09 
 
 
37.8 
PLGA-PEG-GO-NF- 02, 
03, 04 and 05 
(10 min. homogenization) 
 
 
5 
 
1.93 ± 
0.05 
 
 
38.6 
PLGA-PEG-GO-NF- 02, 
03, 04 and 05     
(15 min. homogenization) 
 
 
5 
 
2.25 ± 
0.01 
 
 
45 
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3.II.2.5 SEM: longer exposure time and structural defects 
As mentioned in section 3.I.22, it was observed that longer exposure time to the SEM caused 
structural defects that are presented in Figure 3.II.10 (a-c). 
 
Figure 3.II.10. Represents the structural defects that occurred to the NPs upon long exposure to 
SEM. 
According to Figure 3.II.10 and as mentioned earlier in section 3.I.2.2, it has been observed 
occasionally that long time exposure to electron beams of SEM (longer than 1 min.) can cause 
heating of the mounted samples which causes some merging/fusion of NPs together to form 
clusters. This is because the heat generated by the electron beam of the SEM could melt and 
soften the PLGA walls. This could possibly explain why the tentative sizes obtained from the 
SEM images were found to be much larger than those obtained by the PCS. 
22 
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III. Antibacterial Evaluation of 
PLGA-GO-NPs  
& 
PLGA-PEG-GO-NPs 
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3.III.1 Antibacterial evaluation of PLGA-GO NPs 
3.III.1.1 Antibacterial activities of  mono-dispersed PLGA-GO-NPs 
The antibacterial activities of PLGA-GO-NS-01, NF-01 and NF-06 were tested against E. coli 
and S. aureus using CCM (chapter 2, section 2.3.7). PLGA and GO were used as controls. 
Results are presented in Table 3.III.1 where the % of bacterial inhibition for each formulation is 
presented.  
Table 3.III.1. Presentation of the % of inhibition of PLGA-GO-NS-01, NF-01 and NF-06 
formulations against E. coli and S. aureus. 
 
 
Loaded 
polymer 
 
 
Homogenization 
time 
(min.) 
 
 
Particle size 
range 
(nm) 
 
 
GO % 
(%) 
 
% of bacterial inhibition 
± s.d 
 
 
 
E. coli S. aureus 
PLGA  - 2900-2945 - 0 0 
GO - 3508-3700 - 9.33 ± 
1.15 
10.43 ± 
1.33 
PLGA- 
GO-NS-
01  
5  215-276 50.71 37.67 ± 
0.82 
40.78 ± 
1.85 
10  254-294 52.14 40.67 ± 
         3.93 
46.37 ± 
4.53 
15  245-319 54.85 31.67 ± 
13.59 
34.48 ± 
17.51  
PLGA -
GO-NF-
01 
5  201-219 35.64 36.67 ± 
1.63 
35.97 ± 
3.79 
10  214-223 35.06 38 ± 
0 
39.27 ± 
1.27 
15  221-248 42.18 38 ± 
0 
39.27 ± 
1.27 
PLGA- 
GO-NF-
06 
5  201-213 35.64 36.67 ± 
1.63 
35.97 ± 
3.79 
10  219-223 35.06 38 ± 
0 
39.27 ± 
1.27 
15  224-230 42.18 38 ± 
0 
39.27 ± 
1.27 
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The % of bacterial inhibition of PLGA-GO-NS-01, NF-01 and NF-06 formulations against E. 
coli and S. aureus are represented in Figures 3.III.1 (a-b). 
   
Figure 3.III.1. A comparison between the antibacterial activities of PLGA-GO-NS-01, NF-01 
and NF-06 against (a) E. coli and (b) S. aureus. 
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The antibacterial activity of GO could possibly be due to the organosulphourous compounds 
present in garlic that are able to interact with the sulfa hydryl (SH) groups of bacterial proteins 
causing its denaturation. Besides, garlic is able to interact, through thiol-disulfide exchange, with 
thiol containing enzymes, needed for bacterial metabolism and nutrition, such as alcohol 
dehydrogenase and cysteine proteases. As a result, garlic was reported to be potent antimicrobial 
against a wide range of bacteria such as Helicobacter pylori, Pseudomonas aeruginosa, E. coli, 
Salmonella, S. aureus, Clostridium and streptococcus. Moreover, garlic was reported to be 
effective against many types of fungi and parasites such as Trichomonas vaginalis, Candida 
albicans and Cryputococcus neoformans. 
21, 28, 29, 30 
 Also, it is obvious that PLGA alone shows no antibacterial activities, and all the PLGA-GO-NPs 
formulations presented in Table 3.IIII.1 significantly enhanced the antibacterial activities against 
both E. coli and S. aureus more than the GO in bulk form (control) and these results are in good 
agreement to what has previously been reported considering the enhanced antibacterial activity 
from PLGA NPs containing antibacterial agents. 
65, 105 
From Table 3.III.1, the antibacterial 
activities have significantly increased upon reducing the particle size of GO (3508-3700) by 
more than 10 folds in PLGA-GO composites. More importantly, the antibacterial activities have 
increased by (71-77 %) from the GO % of bacterial inhibition in case of PLGA-GO-NS-01. This 
is significant observation which illustrates the amazing role of controlling the particle size which 
directly affects the antibacterial activity. Similarly, PLGA-GO-NF-01 and NF-06 revealed an 
increase in antibacterial activity by 75 % from the GO % of bacterial inhibition. This could be 
because the GO in bulk form has large particle sizes which decrease the surface area leading to 
minimizing the ability of GO to penetrate the bacterial cell wall. On the other hand, the GO NPs 
have much smaller particle sizes which increase the surface area leading to increasing the contact 
of GO to the bacterial cell wall. The efficiency of GO NPs in inhibiting bacterial growth could 
possibly be because (i) NPs are able to fuse to the bacterial cell wall releasing the conjugated GO 
across the cell wall, (ii) NPs are able to penetrate into the bacterial cells due to their large surface 
areas, (iii) improving the hydrophilicity of GO leading to better delivery of GO to its site of 
action.
106, 107, 108 
(iv) The higher diffusion of the GO NPs through the bacteria more than the GO 
bulk form.
109 
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In addition, all the composite formulations have high negatively charged zeta-potential and as a 
result, the GO NPs will be able to endocytosed by the phagocytic cells, releasing the GO into the 
cells.
109 
This is because it has been reported that increasing the zeta-potentials can increase the 
extent of phagocytosis.
109  
Moreover, according to Table 3.13 and Figure 3.III.1 (a and b), the results revealed that E. coli is 
more resistant than S. aureus for most of the formulations except for PLGA-GO-NF-01 and NF-
06. This is most probably because the gram positive bacteria have a loose poly-glycane outer 
layer that allows the penetration of polymeric NPs conjugated with GO into the cytoplasmic 
membrane allowing the GO to exert its antibacterial action. On the other hand, E. coli has an 
additional outer membrane with a bilayer phospholipid structure that acts as a molecular sieve 
that prevents molecules larger than or equal to 600-1000 Da from penetration into the bacterial 
cytoplasmic membrane.
 65, 104, 105 
In addition, according to Table 3.III.1, one can observe that the antibacterial activities of the NPs 
with particle size rang 200-219 nm are slightly lower than the rest of the NPs presented in Table 
3.III.1. This might be because as the particle sizes decrease, the ability of the NPs to interact with 
the bacterial cell wall and penetrate it decrease.
110 
However,
 
the maximum antibacterial activities 
are observed for the NPs with particle size range 215-294 nm. 
Finally, one can observe that in most of the formulations the antibacterial activities increase with 
increasing the GO % of entrapment within the formulations. 
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3.III.1.2 Antibacterial activities of  poly-dispersed PLGA-GO-NPs 
The antibacterial activities of PLGA-GO-NS-02, 03 and 04, NF-02, 03, 04 and NF-05 were 
tested against E. coli and S. aureus (chapter 2, section 2.3.7) where PLGA and GO were used as 
controls. % of bacterial inhibition for each formulation is presented in Table 3.III.2. 
Table 3.III.2. Presentation of the % of inhibition of different PLGA-GO formulations against E. 
coli and S. aureus. 
 
 
Loaded 
polymer 
 
 
Homogenization 
time (min.) 
 
 
Particle size 
range 
(nm) 
 
 
GO (%) 
 
% of bacterial inhibition ± s.d 
 
E. coli S. aureus 
PLGA  - 2900-2945 - 0 0 
GO - 3508-3700 - 9.33 ± 1.15 10.43 ± 1.33 
PLGA- 
GO-NS-
02  
5  295-309 50.71 19.33 ±1.15 18.53 ± 1.27 
10  329-378 52.14 19.33 ± 1.15 18.53 ± 1.27 
15  337-367 54.85 19.33 ± 1.15 18.53 ± 1.27  
PLGA -
GO-NS-
03 
5  456-498 50.71 18 ± 1.79 19.65 ± 1.69 
10  538-618 52.14 16.33 ± 0.82 17.82 ± 3.43 
15  705-801 54.85 16 ± 16 14.87 ± 1.27 
PLGA- 
GO-NS-
04 
5  243-359 50.71 19.33 ± 1.15 18.53 ± 1.27 
10  415-560 52.14 16.67 ± 1.15 20.77 ± 1.33 
15  390-909 54.85 16 ± 16 14.87 ± 1.27 
PLGA- 
GO-NF-
02 
5  203-236 35.64 36.67 ± 1.63 35.97 ± 3.79 
10  230-263 35.06 40.67 ± 3.93 46.37 ± 4.53 
15  247-285 42.18 40.67 ± 3.93 46.37 ± 4.53 
PLGA- 
GO-NF-
03 
5  221-266 35.64 37.33 ± 1.15 42.3 ± 0 
10  264-308 35.06 31.67 ± 13.59 34.48 ± 17.51 
15  248-334 42.18 31.67 ± 13.59 34.48 ± 17.51 
PLGA- 
GO-NF-
04 
5  203-239 35.64 36.67 ± 1.63 35.97 ± 3.79 
10  180-251 35.06 36.33 ± 1.51 37.48 ± 5.34 
15  188-368 42.18 27.33 ± 8.82 25.6 ± 7.82 
PLGA- 
GO-NF-
05 
5  202-215 35.64 36.67± 1.63 35.97 ± 3.79 
10  223-239 35.06 38 ± 0 39.27 ± 1.27 
15  219-239 42.18 38  ± 0 39.27 ± 1.27 
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The % of bacterial inhibition of PLGA-GO-NS-02, 03 and 04, NF-02, 03, 04 and 05 NF 
formulations against E. coli and S. aureus are represented in Figures 3.III.2 (a-b). 
 
Figure 3.III.2. A comparison between the antibacterial activities of different PLGA-GO-NPs 
against (a) E. coli and (b) S. aureus. 
Table 3.III.2 showed that the antibacterial activities have increased by (42-52 %) in case of 
PLGA-NS (02, 03 and 04), and by (71-77 %) in case of PLGA-GO-NF (02, 03, 04 and 05) from 
the original GO % of bacterial inhibition. The antibacterial activities are dependent on the 
particle sizes in which the results are fluctuating. One can observe that the antibacterial activities 
95 
 
of the NPs with particle sizes above 295 nm (PLGA-GO-NS-02, 03 and 04) are much lower than 
that with particle sizes less than 295 nm (PLGA-NF-02, 03, 04 and 05). This might be because 
large NPs compete with the small ones and prevent them from penetrating the bacterial cell wall.  
Furthermore, the results showed that the solution settling, filtration through a biological filter and 
Buchner funnel are crucial steps that significantly enhanced the antibacterial activities of the 
PLGA-GO formulations.  This is because large particles are removed and the small ones 
remained and resulting in decreasing the aggregation of NPs and increasing their surface areas 
(as mentioned earlier in section 3.I.2.1). This, in turn, results in increasing the interaction 
between the NPs and the bacterial cell wall and thus leading to greater contact of GO with the 
cell surface of bacteria.
107, 108, 110, 111 
Moreover, it is obvious that the antibacterial activities are dependent on the particle sizes rather 
than the GO %, on the contrary to the mono-dispersed NPs. 
In summary, it is obvious that the maximum antibacterial activities are achieved for the NPs with 
size range (215-295) where any decrease or increase in the particle sizes below or above this 
range can decrease the antibacterial activity against both bacteria. Also, it is noticeable that the 
presence of particles with different sizes (more poly-dispersed) causes fluctuations in some of 
the antibacterial activities.  Finally, it is obvious that Buchner filtration of the nano-suspension 
forming the PLGA-GO-NFs was essential to enhance the antibacterial activities of the GO nano-
formulations. 
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3.III.2  Antibacterial evaluation of PLGA-PEG-GO NPs 
3.III.2.1 Antibacterial activities of  mono-dispersed PLGA-PEG-GO-NPs 
The antibacterial activities of PLGA-PEG-GO-NS-01, NF-01 and NF-06 were similarly tested 
against E. coli, and S. aureus using CCM (chapter 2, section 2.3.7). PLGA, PEG and GO were 
used as controls. The % of inhibition for each formulation is presented in Table 3.III.3. 
Table 3.III.3 Presentation of the % of inhibition of PLGA-PEG-GO-NS-01, NF-01 and NF-06 
formulations against E. coli and S. aureus. 
 
 
Loaded 
polymer 
 
 
Homogenization 
time 
         (min.) 
 
 
Particle 
size range 
(nm) 
 
 
     GO % 
 
% of bacterial inhibition ± 
s.d 
 
 
 
E. coli S. aureus 
PLGA  - 2900-2945 - 0 0 
PEG - 1770-1975 - 0 0.23 ± 
0.05 
PLGA+PEG - 4034-5184 - 0 0.2 ± 
0 
GO - 3508-3700 - 9.33 ± 
1.15 
10.43 ± 
1.33 
PLGA-
PEG- GO-
NS-01  
5  229-240 51.6 39.67 ± 
3.44 
41.15  ± 
5.4 
10  232-244 55.8 39.67 ± 
3.44 
41.15  ± 
5.4 
15  264-293 62.6 33 ± 
4.151 
37.8 ± 
1.97 
PLGA-PEG 
-GO-NF-01 
5  170-212 37.8 19 ± 
1.1  
28.17 ± 
9.82 
10  190-225 38.6 30.67 ± 
13.19 
41.52 ± 
5.01 
15  205-237 45 30.67 ± 
13.19 
41.52 ± 
5.01 
PLGA-
PEG- GO-
NF-06 
5  184-189 37.8 19.33 ± 
1.15 
19.27 ± 
1.27 
10  181-219 38.6 31 ± 
12.82 
32.62 ± 
14.67 
15  199-227 45 30.67 ± 
13.19 
41.52 ± 
5.01 
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The % of bacterial inhibition of PLGA-PEG-GO-NS-01, NF-01 and NF-06 formulations against 
E. coli and S. aureus are represented in Figure 3.III.3 (a-b). 
 
Figure 3.III.3 A comparison between the antibacterial activities of different PLGA-PEG-GO-
NS-01, NF-01 and NF-06 against (a) E. coli and (b) S. aureus. 
According to Table 3.III.3 and Figure 3.III.3 (a and b), the results revealed that E. coli is more 
resistant than S. aureus for most of the formulations, and this could also be explained similarly 
with the same reasons mentioned earlier in section 3.III.1.1.  
 
98 
 
Also, it is obvious that all the PLGA-PEG-GO-NPs formulations presented in Table 3.III.3 
significantly enhanced the antibacterial activities against both E. coli and S. aureus more than the 
GO in bulk form (3508-3700 nm) and these results are in good agreement to what has previously 
been reported considering the enhanced antibacterial activity from PLGA-PEG NPs containing 
antibacterial agents.
65, 105  
The antibacterial activities have increased by (71-76%) from the GO % 
of bacterial inhibition in case of NS-01 formulation and (51-69 %) in case of NF-01 and NF-06. 
The efficiency of GO NPs in inhibiting bacterial growth more than the GO (bulk form) was 
explained earlier in section 3.III.1.1  
Furthermore, the results showed that the solution settling, filtration through a biological filter and 
Buchner funnel are crucial steps that significantly enhanced the antibacterial activities of the 
PLGA-PEG-GO formulations. However, results showed that when the particle sizes are 
decreased beyond 200 nm, the antibacterial activities decreased (but still higher than that of bulk 
GO). This might be because the NPs less than 200 nm have weaker interactions with the 
bacterial cell wall.  
Also, it is obvious that the PLGA-GO formulations have stronger antibacterial activities than 
PLGA-PEG-GO formulations and this is not related to the GO %, as PLGA-PEG-GO NPs have 
higher GO % than PLGA-GO NPs. The enhanced antibacterial activities of the formulations 
without PEG over those containing PEG is probably related to the decreased zeta-potential of 
PLGA-PEG-GO formulations resulting in decreasing the extent of phagocytosis. 
109 
Moreover, 
the PLGA-PEG-GO formulations are much hydrophilic than PLGA-GO formulations leading to 
reducing the ability of NPs to penetrate the hydrophobic cell wall of bacteria. 
3.III.2.2 Antibacterial activities of  poly-dispersed PLGA-PEG-GO-NPs 
The antibacterial activities of  PLGA-PEG-GO-NS-02, 03 and 04, NF-02, 03, 04 and NF-05 
were tested against E. coli, and S. aureus using CCM (chapter 2, section 2.3.7) where PLGA, 
PEG and GO were used as controls. Results are presented in Table 3.III.4 where the % of 
bacterial inhibition for each formulation is presented.  
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Table 3.III.4. Presentation of the % of inhibition of different PLGA-PEG-GO formulations 
against E. coli and S. aureus. 
 
 
Loaded 
polymer 
 
 
Homogenization 
time 
          (min.) 
 
 
Particle 
size 
range 
(nm) 
 
 
 
GO (%) 
 
% of bacterial inhibition ± s.d 
 
 
 
E. coli S. aureus 
PLGA  - 2900-
2945 
- 0 0 
PEG - 1770-
1975 
- 0 0.23 ± 0.05 
PLGA+PEG - 4034-
5184 
- 0 0.2 ± 0 
GO - 3508-
3700 
- 9.33 ± 1.15 10.43 ± 1.33 
PLGA-
PEG- GO-
NS-02  
5  254-265 51.6 36.67 ± 1.154 36.33 ± 1.27 
10  271-280 55.8 36 ± 7.38 42.62 ± 3.84 
15  315-327 62.6 23.33 ± 6.77 28.17 ± 12.21 
PLGA-PEG 
-GO-NS-03 
5  425-477 51.6 17.33 ± 2.31 17.07 ± 1.27 
10  653-755 55.8 17.33 ± 2.31 17.07 ± 1.27 
15  743-817 62.6 17.33 ± 2.31 17.07 ± 1.27 
PLGA-
PEG- GO-
NS-04 
5  239-391 51.6 23.33 ± 6.77 28.17± 12.21 
10  251-627 55.8 17.33 ± 2.31 17.07 ± 1.27 
15  343-922 62.6 17.33 ± 2.31 17.07 ± 1.27 
PLGA- GO-
NF-02 
5  204-219 37.8 30.67 ± 13.19 41.52 ± 5.01 
10  207-254 38.6 30.67 ± 13.19 41.52 ± 5.01 
15  237-271 45 30.67 ± 13.19 36.33 ± 1.27 
PLGA-
PEG- GO-
NF-03 
5  226-235 37.8 30.67 ± 13.19 41.52 ± 5.01 
10  233-268 38.6 30.67 ± 13.19 36.33 ± 1.27 
15  248-304 45 33 ± 4.15 37.8 ± 1.97 
PLGA-
PEG- GO-
NF-04 
5 205-229 37.8 30.67 ± 13.19 41.52 ± 5.01 
10  204-233 38.6 30.67 ± 13.19 41.52 ± 5.01 
15  217-244 45 30.67 ± 13.19 41.52 ± 5.01 
PLGA-
PEG- GO-
NF-05 
5  186-205 37.8 31 ± 12.82 32.62 ± 14.69 
10  192-230 38.6 30.67 ± 13.19 41.52 ± 5.01 
15  203-236 45 30.67 ± 13.19 41.52 ± 5.01 
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The % of bacterial inhibition of PLGA-PEG-GO-NS-02, 03 and 04, NF-02, 03, 04 and 05 NF 
formulations against E. coli and S. aureus are represented in Figures 3.III.4 (a-b). 
 
Figure 3.III.4. A comparison between the antibacterial activities of different PLGA-PEG-GO-
NPs against (a) E. coli and (b) S. aureus. 
Table 3.III.4 showed that the antibacterial activities are dependent on the particle sizes. Upon 
solution settling, filtration through biological filter and Buchner funnel, the particle sizes and 
PDI decreased causing the antibacterial activities to be enhanced as explained earlier in section 
3.III.2.1. 
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PLGA-PEG-GO-NS-01, NF-01 and NF-06 have a pronounced antibacterial activity against both 
E.coli and S. aureus more than PLGA-PEG-GO-NS-02, 03 and 04, NF-02, 03, 04, and 05.This is 
because large particles are removed and small ones are kept resulting in decreasing the 
aggregation of NPs and increasing their surface areas (as mentioned earlier in section 3.I.2.1) 
resulting in increasing the interaction between the NPs and the bacterial cell wall leading to  
greater contact of GO with the cell surface of bacteria.
107, 108, 110, 111 
Moreover, the results revealed that the PLGA-GO formulations have higher % of bacterial 
inhibition than PLGA-PEG-GO formulations except for PLGA-PEG-GO-NS-02 which is higher 
than PLGA-GO-NS-02 as explained earlier. On the other hand, PEG increases the GO content % 
and improves the release and penetration of GO outside the polymeric matrix.
110
 In addition, the 
NPs prepared with the addition of PEG have much uniform size distributions and smaller particle 
sizes than that prepared without PEG. Moreover, it is noticeable that the presence of particles 
with different sizes (more poly-dispersed) causes fluctuations in some of the antibacterial 
activities.   
From the overall results, one can conclude that the addition of PEG to the formulations improves 
the physicochemical properties e.g. higher drug content efficiencies, smaller sizes and narrower 
PDI(s), but the antibacterial activities decrease lower than that of PLGA-GO formulations. 
Moreover, it was shown that the antibacterial activities increased when Buchner filtration was 
carried out in both PLGA-GO and PLGA-PEG-GO preparations, but no relation was observed 
between the homogenization time intervals and antibacterial activities. 
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Chapter 4 
 
Comparative Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Microscopic images 
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4. Comparative study 
According to sections 3.I.1 and 3.II.1, by comparing the average particle sizes and particle size 
distributions of PLGA-GO (NS-01, NF-01 and NF-06) and PLGA-PEG- GO (NS-01, NF-01 and 
NF-06), it was observed that the PLGA-PEG-GO formulations have much smaller average 
particle sizes and particle size distributions than PLGA-GO formulations. This might be due to 
what has previously been reported, PEG acts as a surfactant that produces uniform finer 
emulsion droplets through lowering the interfacial tension of the emulsion during the NPs 
preparation.
(95-98)
As a result, PLGA-PEG-GO formulations are much stable in suspension than 
PLGA-GO formulations because they have lower sizes and narrower PDIs.   Moreover, it was 
shown that the average zeta potential of PLGA-PEG-GO formulations are lower than that of 
PLGA-GO formulations. This is because as has previously been reported, coating of the NPs 
with surfactants such as PEG (amiphiphilic polymers) reduces the zeta potential because the 
coating layers can mask the surface charge of the uncapped end carboxylic groups of the 
polyester. This proves that part of the surfactant molecules are located on the surface of the NPs 
producing lower zeta potential values.
89, 101  
On comparing the homogenization time intervals for both PLGA-GO and PLGA-PEG 
formulations, we found that the average particle sizes increase upon increasing the 
homogenization time from 5 to 10 to 15 min, (at the same homogenization speed of 11,000 rpm). 
This could possibly be because as the homogenization time increases, the high shear stress of the 
homogenizer will result in the aggregation of the colloidal particles into larger ones, and thus 
increasing the PDI. In addition, PLGA might get melted by the high energy, due to the high 
homogenization speed, leading to the instability of the particles.
85 
In addition, it was observed 
that the average particle sizes of NFs are smaller than that of NSs and the NPs are much uniform. 
This might be because Buchner filtration removed the large, unstable particles and kept the 
small, stable ones resulting in the formation of NPs that are much stable and uniform in size. 
According to sections 3.I.1.4 and 3.II.1.4, on comparing the GO% in both PLGA-GO and 
PLGA-PEG-GO formulations, it was observed that PLGA-PEG-GO formulations contain higher 
GO% than PLGA-GO formulations. This is because PEG coats the NPs forming a barrier that 
surrounds and protects GO reservoir resulting in protecting GO during emulsification and keeps 
its stability.
98 
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On comparing the effect of homogenization time and Buchner filtration on the GO% in PLGA-
GO and PLGA-PEG-GO formulations, we observed that the GO% increases upon increasing the 
homogenization time from 5 to 10 to 15 min, and this might be attributed to the longer 
homogenization time allowing the GO to be effectively incorporated within the PLGA NPs. On 
the other hand, the GO% decreases upon filtration through Buchner funnel (GO% in NSs is 
higher than that in NFs), this could be possibly because of the high pressure applied by vacuum 
during Buchner filtration causes the leakage of GO outside the PLGA NPs, but still the GO % in 
the PLGA-GO-NFs is reasonable and sufficient to exert the antibacterial action. 
According to sections 3.III.1 and 3.III.2, the antibacterial results revealed that all the prepared 
nano-formulations conjugated with GO have higher antibacterial activities than the original GO 
against gram negative and gram positive bacteria. The efficiency of GO NPs in inhibiting 
bacterial growth could possibly be because NPs are able to fuse to the bacterial cell wall 
releasing the conjugated GO across the cell wall. In addition, NPs are able to penetrate into 
bacterial cells due to their large surface areas and improving the hydrophilicity of GO leading to 
better delivery of GO to its site of action. 
(106-108) 
It was shown that solution settling, Filtration through a biological filter and Buchner funnel are 
essential steps that significantly enhanced the antibacterial activities of the different 
formulations. This is because large particles are removed and small ones are kept resulting in 
decreasing the aggregation of NPs and increasing their surface areas resulting in increasing the 
interaction between the NPs and the bacterial cell wall leading to greater contact of GO with the 
cell surface of bacteria.
107, 108, 110 
However, results showed that when the particle sizes are 
decreased beyond 200 nm, the antibacterial activities decreased (but still higher than that of bulk 
GO). This might be because the NPs less than 200 nm have weaker interactions with the 
bacterial cell wall. Also, large NPs beyond 295 nm decrease the antibacterial activities. This 
might be because large NPs compete with the small ones and prevent them from penetrating the 
bacterial cell wall. 
On comparing the antibacterial activities of both PLGA-GO and PLGA-PEG-GO formulations, it 
was observed that the antibacterial activities of PLGA-PEG-GO formulations are lower than that 
of PLGA-GO formulations.  This might be because adding PEG to the formulations decreased 
the particle sizes resulting in decreasing their abilities to attach to the bacterial cell wall. In 
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addition, the NPs prepared with the addition of PEG have much uniform size distributions and 
smaller particle sizes than that prepared without PEG. 
The main differences between PLGA-GO NPs and PLGA-PEG-GO NPs are summarized in 
Table 4.1 where we recommend the formulations prepared at 5 min. homogenization time 
interval because they save time and produce NPs that are smaller in size, more stable and 
uniform in sizes. 
Table 4.1 A summary between the major outcomes of both PLGA-GO and PLGA-PEG-GO 
NPs. 
 PLGA-GO NPs PLGA-PEG-GO NPs 
1-Particle size ranges Higher Lower 
2-Zeta-potential Higher –ve charges Lower –ve charges 
3- GO% Lower Higher 
4-Morphology Common spherical particles Common spherical particles 
5-Antibacterial activity Higher Lower 
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Figure 5.5: Microscopic images 
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Conclusions 
The work described here is mainly focused on the preparation of uniform and stable polymer 
(PLGA and PLGA-PEG) mixed with GO to form composite NPs (PLGA-GO and PLGA-PEG-
GO NPs) with small monodisperse particle sizes (≤200nm) and a pronounced antibacterial 
activities. Surprisingly, we found that some factors (challenges) affect the physicochemical 
properties of the NPs during the preparation steps such as homogenization time (5, 10 and 15 
min.) at the same homogenization speed (11,000rpm), settling of the solutions, and solution 
filtration through Buchner funnel and biological filters. Buchner filtration was carried out to the 
nano-suspensions followed by settling of the filtrate and re-filtration through biological filters in 
order to overcome the challenges that affect the stability and average particle sizes of the NPs.  
From the overall results, the results revealed that filtration through Buchner funnel and biological 
filters (forming polymeric NFs) have a significant effect on decreasing the average particle sizes, 
increasing the stability of the NPs and enhancing the antibacterial activities against both gram 
positive and negative bacteria. In addition, the results showed that the addition of PEG to the 
PLGA-GO formulations (to form PLGA-PEG-GO NPs) improves the physicochemical 
properties such as higher GO content efficiencies, smaller particle sizes and narrower PDI(s), but 
the antibacterial activities were slightly decreased except for the formulation prepared at 5 min. 
homogenization time.  
In addition, the results revealed  that all prepared polymeric NPs conjugated with GO in this 
study, with or without incorporating PEG as a surfactant, have shown stronger antibacterial 
activities against both gram positive and negative bacteria more than the original GO. 
Furthermore, it is obvious that the formulations prepared at homogenization time interval of 5 
min. have better physicochemical properties than those prepared at homogenization time 
intervals of 10 and 15 min. On the other hand, it was observed that increasing homogenization 
time intervals (from 5 to 10 to 15 min.) increased the GO % within the formulations. 
Finally, it was shown that the antibacterial activities increased when Buchner filtration was 
carried out, but no relation was observed between the homogenization time intervals and 
antibacterial activities. 
 
108 
 
 
Future perspectives: 
The PLGA-PEG NPs system prepared in this study could be used as a good delivery system not 
only for GO, but also for other hydrophilic and hydrophobic drugs. As the drug content 
efficiency increases, large single dose can be administered instead of small frequent doses and by 
enhancing the NPs stability, the drugs half –life would be prolonged inside the human body 
decreasing the administration frequency.  
Further release, in-vitro studies on normal cells as well as in-vivo studies on animals and clinical 
studies are recommended to be carried out on the PLGA-GO- and PLGA-PEG-GO formulations 
prepared at 5 min. homogenization time in this work.  
Also, GO could be replaced with other drugs such as insulin, somatotropine, hormones or anti-
cancer agents. As the PLGA-GO and PLGA-PEG-GO formulations prepared in this study could 
allow the oral administration of different drugs instead of direct I-V injection which would offer 
more patients compliance.  
In addition, the PLGA-GO and PLGA-PEG prepared in this work could be promising in 
improving the solubility of poorly water soluble drugs, decreasing the volatility of volatile drugs 
and enhancing the targeted delivery of different drugs, leading to increasing the efficiency and 
decreasing the systemic side effects. 
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